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ABSTRACT
MITIGATING CISPLATIN RESISTANCE IN OVARIAN CANCER
Clarisse S. Muenyi
July 21, 2011
Epithelial Ovarian cancer (EOC) is the leading cause of gynecological
cancer death in the USA. Recurrence rates are high after front-line platinum
chemotherapy and most patients eventually die from platinum-resistant disease.
P53 plays an important role in cellular response to platinum-DNA
damage. It transcriptionally activates XPC, a platinum-DNA damage recognition
protein in the global genome repair (GGR), sub-pathway of nucleotide excision
repair (NER). The goal of this research is to investigate the effect of a novel
combination of cisplatin, sodium arsenite (NaAs0 2 ) and hyperthermia (CPA 39
DC) on EOC cells with different p53 status. Human EOC cells were treated with
cisplatin ± 20 IJM NaAs0 2 for 1 h at 37 or 39°C. NaAs0 2 ± hyperthermia
selectively sensitized wild-type p53 EOC cells to cisplatin by suppressing XPC
and enhancing cellular and DNA platinum accumulation. In contrast, only
hyperthermia sensitized p53-mutated and p53-null EOC cells to cisplatin by
enhancing cellular and DNA platinum accumulation. Cisplatin ± NaAs0 2 at 37 or
39°C induced pseudo-G1 associated apoptosis in p53 expressing cells.
Co-treatment with HSP90 inhibitor 17-DMAG plus CPA 39°C greatly
sensitized EOC cells by enhancing cellular platinum accumulation. In order to
vi

translate the in vitro findings in an in vivo model, metastatic ovarian cancer was
established in nude mice by intraperitoneal injection of A2780/CP70 human EOC
cells. Tumor bearing mice were perfused with 3 mg/kg body weight (BW) cisplatin

± 26 mg/kg BW NaAs02 for 1 h at 37 or 43°C using a murine intraperitoneal
chemotherapy system developed in our laboratory. Cisplatin induced NER
proteins XPC and XPA and suppressed mismatch repair protein MSH2 that is
associated with resistance. However, co-treatment with NaAs0 2 at 37 or 43°C
suppressed XPC, restored higher levels of MSH2 and enhanced tumor platinum
uptake. Platinum and arsenic generally accumulated in systemic tissues during
intraperitoneal lavage and decreased 24 h after perfusion.
In conclusion, CPA 39 °C alone or combined with 17-DMAG has the
potential to sensitize EOC to cisplatin by attenuating NER, activating mismatch
repair, enhancing tumor platinum accumulation and activating apoptotic cell
death.
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CHAPTER 1
GENERAL INTRODUCTION
Every year, about 225,000 women are diagnosed with ovarian cancer
(OC) worldwide and more than 50% of these patients die from the disease,
making OC the

ih leading cause of cancer death in women globally (Jemal, et

aI., 2011). In the United States, an estimated 21,880 women were diagnosed
with OC in 2010 and 13,850 died from the disease (Jemal, et aI., 2010), making
OC the leading cause of gynecological cancer death in the U.S. The high death
rate is due to tumor spread beyond the ovary at the time of diagnosis and both
innate and acquired resistance to chemotherapeutics (Cannistra, 2004).
The front-line treatment for advanced OC is cytoreductive surgery to
excise the bulk of tumors followed by intravenous (IV) or combined IV and
intraperitoneal (IP) cisplatin or carboplatin in combination with taxane therapy
(McGuire, et aI., 1996; Vasey, et aI., 1999; Armstrong, et aI., 2002; Markman,
1988). Although most women initially respond to treatment, the disease recurs in
60 - 70% of women with very poor prognosis (Ozols, 2005; Rubin, et aI., 1999).
Recurrent tumors that initially responded to platinum become resistant. In
addition to this 'acquired' resistance, about 25% of OC are 'innately' resistant to
platinum and respond poorly to initial chemotherapy.
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Acquired or innate resistance to platinum compounds is a major limitation
to clinical success. Ways of mitigating drug resistance include: increasing dose,
changing route of drug administration or combining therapies. Increasing the
dose of platinum agents will increase the risk for adverse side effects such as
kidney failure (Zhang, et aI., 2007). Changing route of drug delivery from
intravenous to intraperitoneal makes sense because metastatic DC is usually
confined to the peritoneal cavity. The rationale for intraperitoneal therapy in DC
treatment is that tumors will receive sustained exposure to high concentrations of
drugs while the peritoneal lining will protect against systemic distribution of drugs
to limit toxicity (Echarri Gonzalez, et aI., 2011). In response to three large
randomized clinical trials showing benefit to incorporating intraperitoneal (lP)
delivery in DC, the National Cancer Institute issued a clinical announcement
recommending that patients with small volume disease at the end of frontline
surgery be offered the chance of receiving IP chemotherapy (Trimble and
Christian, 2008). Adding hyperthermia to chemotherapy agents delivered
intraperitoneally (HIPEC) could improve outcome (Helm, 2009; Yang, et aI.,
2010; Dovern, et aI., 2010).
Cisplatin is a potent chemotherapeutic against various forms of solid
tumors including ovarian (Vasey, et aI., 1999), testicular (Duale, et aI., 2007) and
bladder cancer (Ecke, et aI., 2006). In vitro cell culture studies have shown that
the cytotoxicity of cisplatin and its analogues such as carboplatin and oxaliplatin
is directly related to total platinum bound to DNA (Knox, et aI., 1986).
Development of resistance to platinum drugs is a major challenge in

2

chemotherapy. Mechanisms of cisplatin resistance are multifactorial and include:
decreased drug accumulation, enhanced detoxification by glutathionylation and
efflux by multi-drug resistance proteins or binding to metallothionein, elevated
DNA repair and DNA damage tolerance (Parker, et aI., 1991; Stewart, 2007). The
consequence of these mechanisms of resistance is decreased cell kill. In order to
enhance OC cell kill, combined hyperthermia and platinum-based
chemotherapeutics delivered intraperitoneally (HIPEC) has been used to treat
women with advanced OC (Dovern, et aI., 2010; Helm, et aI., 2008).
Hyperthermia enhances cisplatin cytotoxicity (Akaboshi, et aI., 1994; Alberts, et
aI., 1980; Hahn, 1979; Herman, et aI., 1988; Los, et aI., 1994). Hyperthermia
enhances the penetration of cisplatin into peritoneal tumor implant when
delivered intraperitoneally (van, V, et aI., 1998) and also enhances platinum-DNA
adduct formation (Meyn, et aI., 1980; van, V, et aI., 1998). In addition,
hyperthermia causes cellular stress and induces mitotic catastrophe
(Hildebrandt, et aI., 2002; Sekhar, et aI., 2007). Even though HIPEC therapy
increases survival, complete remission is not attained (Dovern, et aI., 2010).
Failure to achieve complete remission could be due to heat loss or uneven
temperature distribution during HIPEC. Thus, there is need for pharmacological
agents that will enhance the effect of hyperthermia on platinum-based
chemotherapy. Arsenic has the potential to enhance hyperthermia cytotoxicity
effect on cisplatin. Arsenic can potentially inhibit mechanisms of cisplatin
resistance and also enhance mechanisms of hyperthermia induced cell death
(Helm and States, 2.009; Muenyi, et aI., 2011).
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Arsenic has a paradoxical effect because it is a chemotherapeutic as well
as an environmental hazard (Desoize, 2004; Cui, et aL, 2008). Arsenic (Fowler's
solution (KAS02)) has been used as a chemotherapeutic to treat chronic
myelogenous leukemia before the advent of radiation therapy (Waxman and
Anderson, 2001). Arsenic trioxide (As 2 0 3) has been used in Chinese traditional
medicine for hundreds of years. The Food and Drug Administration approved the
use of Trisenox® (As2 0 3) for the treatment of all-trans retinoic acid (ATRA)
resistant acute promyelogenous leukemia in 2001 (Cohen, et aL, 2001). There
are several clinical trials underway using Trisenox® (As2 0 3) to treat
hematological and solid tumors (Murgo, 2001; Murgo, et aL, 2000).
Mechanisms of arsenic induced cytotoxicity include: inhibition of
nucleotide excision repair (Hartwig, et aL, 1997; Hartwig, et aL, 2003; Nollen, et
aL, 2009; Muenyi et aL, 2011), causation of oxidative stress (Shi, et aL, 2004b;
Shi, et aI., 2004a), induction of mitotic catastrophe (Taylor, et aL, 2008; McNeely,
et aL, 2008a) and induction of apoptotic cell death (HU, et aL, 2005; Ramos, et
aL, 2005). Resistance to arsenic is associated with enhanced metallothionein
binding, detoxification by glutathione conjugation and efflux by multi-drug
resistance proteins (Leslie, et aL, 2004), similar to cisplatin and its analogues
(Cole, et aL, 1994; Byun, et aL, 2005; Surowiak, et aL, 2005). Therefore, arsenic
and platinum are expected to compete for the detoxification and efflux pathways.
Hence, it is reasonable to predict that co-treatment with arsenic and cisplatin may
increase the intracellular accumulation of platinum via competition for the
detoxification and efflux systems. Increased cellular accumulation will likely

4

increase the amount of platinum binding to DNA and thus, increase cell death.
Furthermore, arsenic mimics hyperthermia because it also causes mitotic
catastrophe (Taylor, et aI., 2006; McNeely, et aI., 2008b; McNeely, et aI., 2008a)
and induces cellular stress similar to hyperthermia (Del Razo, et aI., 2001).
The cytotoxicity of platinum-based chemotherapeutics is mediated through
high levels of DNA damage leading to apoptosis, DNA repair, or cell cycle arrest.
Cellular response to platinum-DNA damage is mediated through ATMIATR and
CHK1/CHK2 (8asu and Krishnamurthy, 2010) that phosphorylate and activate
the tumor suppressor protein p53 (Canman, et aI., 1998). P53 regulates cell
death and cell survival following DNA damage. The role of p53 is to maintain the
integrity of the genome. Thus, it is known as the "guardian of the genome"
(Efeyan and Serrano, 2007). Activated p53 induces cell cycle checkpoint
activation, apoptosis and DNA repair protein expression (Harris and Levine,
2005; Ford, 2005). Cisplatin is known to cause G2 arrest. P53 regulates G2/M
transition by transcriptionally activating cyclin dependent kinase (CDK) inhibitor
CDKN1A, GADD45 and 14-3-30" (Abraham, 2001). These proteins inhibit
CDK1/cyclin 8 and block entry into mitosis. Arsenic causes mitotic arrest and
both arsenic and hyperthermia induce mitotic catastrophe (Taylor, et aI., 2008;
McNeely, et aI., 2008a). Thus, it will be interesting to determine if arsenic and
hyperthermia induce mitotic catastrophe in cisplatin treat cells.
Cisplatin forms bulky DNA adducts by binding to the N7 position of
adjacent guanines to form predominantly intrastrand cross links and to a lesser
extent interstrand cross links by linking guanines on opposite strands at CpG
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sites. The bulky lesions resulting from intrastrand cross links are repaired
primarily by the nucleotide excision repair (NER) pathway (Wood, 1996).
Resistance to cisplatin is associated with enhanced NER (Martin, et aI., 2008).
There are five main steps involved in NER: damage recognition, assembly of
repair complex, excision of damage, gap filling and ligation (Figure 1). There are
two sub-pathways of NER: global genome repair (GGR) and transcription
coupled repair (TCR). GGR removes DNA damage from the entire genome
whereas TCR repairs DNA damage only on actively transcribing strands. These
two pathways differ only in the lesion recognition step. In TCR, a stalled RNA
polymerase II at the region of damage and Cockayne syndrome A and B (CSA
and CSB) recognize damage on actively transcribing genes. In GGR, XPC and
DDB2 are involved in DNA damage recognition (Fitch, et aI., 2003). P53
regulates DNA repair by transcriptionally regulating XPC and DDB2 (Adimoolam
and Ford, 2003; Ford and Hanawalt, 1995; Ford, 2005; Ford and Hanawalt,
1997). XPC is actively involved in cisplatin-DNA damage recognition (Neher, et
aI., 2010). Arsenic inhibits NER by suppressing XPC in fibroblast (Nollen, et aI.,
2009). This suggests that arsenic will sensitize OC cells to cisplatin by inhibiting
XPC.
Following DNA damage recognition, downstream repair proteins XPA,
RPA, ERCC1, TFIIH, DNA polymerase 8 and DNA ligase are recruited to repair
the damage in a common pathway (Figure 1). Over-expression of XPA and
ERCC1 mRNA has been associated with cisplatin resistance in OC (Dabholkar,
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et aI., 1994). Thus, understanding if arsenic and hyperthermia modulate the
expression of XPA and ERCC1 in order to sensitize cells to cisplatin is needed.
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Figure 1. Nucleotide exicision repair pathway. The nucleotide excision repair
pathway indicating the two sub-pathways: transcription coupled repair and global
genome repair. This Figure was adapted from Paul Porter's dissertation.
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In addition to NER, the mismatch repair (MMR) pathway has been
implicated in cisplatin resistance (Fink, et aI., 1997). In an effort to repair
platinum-DNA damage by the MMR pathway, a futile MMR occurs leading to cell
death (Martin, et aI., 2008; Topping, et aI., 2009). Ovarian cancer cells overexpressing MMR proteins such as MSH6 and MSH2 are sensitive to cisplatin
(Ding, et aI., 2009; Pani, et aI., 2007; Topping, et aI., 2009). Therefore, it is
important to determine if arsenic and hyperthermia sensitize cells to cisplatin by
activating the MMR pathway.
Although there has been tremendous effort in recent years to enhance the
efficacy of platinum-based chemotherapy against OC by changing route of drug
delivery and using combination therapy, over 50% of OC patients still die
annually. The low response to chemotherapy and high death rate could be due to
the heterogeneity of cancer cell population that result from constant mutation and
alteration of important genes such as p53. This heterogeneous population of
cancer cells cannot be treated successfully by a single agent or combination of
drugs designed for a single target or cellular pathway. The need for combination
therapy with each drug aimed at different targets or cellular pathways is
paramount. In the following studies, I investigated the cytotoxicity effect of a new
combination of sodium arsenite and hyperthermia on cisplatin cytotoxicity on a
panel of OC cells expressing wild-type p53 or that are p53-null or p53-mutated. I
used cells with different p53 status because about 50% of OC cells have nonfunctional p53 (Schuijer and Berns, 2003). In addition, p53 transcriptionally
regulates genes involved in platinum-DNA damage repair (Ford, 2005).
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Therefore, understanding how p53 status affects response to combined cisplatin,
sodium arsenite and hyperthermia is important. I also examined how sodium
arsenite and hyperthermia alter the mechanisms of cisplatin resistance.
Particularly I examined the effects of sodium arsenite and hyperthermia on
cellular and DNA accumulation of platinum, platinum-DNA repair pathways,
induction of cellular stress, mitotic arrest/mitotic catastrophe induction and cell
cycle regulation. I used both in vitro cell culture and human DC xenograft models
for these studies. Cytotoxicity data indicate that combined cisplatin, sodium
arsenite and hyperthermia sensitized wild-type p53 expressing human DC cells
to cisplatin by suppressing p53 regulated protein XPC, enhancing cellular and
tumor accumulation of platinum and enhancing platinum bound to DNA. I also
observed that sodium arsenite ± hyperthermia suppressed XPC and enhanced
platinum accumulation in metastatic tumors. Inhibition of the activity of stress
response protein HSP90 greatly potentiated the cytotoxicity of combined
cisplatin, sodium arsenite and hyperthermia in a p53-independent manner.
Cisplatin, sodium arsenite and hyperthermia induced pseudo-G1 arrest
associated apoptosis in p53 expressing cells.
In conclusion, combined cisplatin, sodium arsenite and hyperthermia (CPA
39°C) or CPA 39 °c plus 17-DMAG has the potential to sensitize DC to cisplatin
by suppressing NER, activating mismatch repair and enhancing cellular and DNA
platinum accumulation, causing cellular stress and inducing apoptotic cell death.
This combination chemotherapy will be effective because each of these drugs
has a different mechanism of action.
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CHAPTER 2
COMBINED SODIUM ARSENITE AND HYPERTHERMIA SELECTIVE
SENSITIZATION OF WILD-TYPE P53 HUMAN OC CELLS TO CISPLATIN
INVOLVES SUPPRESSION OF XPC AND ENHANCEMENT OF CELLULAR
AND DNA PLATINUM ACCUMULATION
INTRODUCTION

Epithelial Ovarian cancer (OC) is the leading cause of gynecological
cancer death among women in the United (Jemal, et aI., 2010). Cisplatin and its
analogues are front-line drugs to treatment OC (Armstrong, et aI., 2002).
Cisplatin causes DNA damage to induce cell death (Cepeda, et aI., 2007).
However, cellular processes such as enhanced platinum-DNA damage tolerance,
platinum-DNA repair, cisplatin metabolism and cellular export and reduced
accumulation confer resistance to cisplatin (Stewart, 2007), and thus decrease
the effectiveness of cisplatin.
Combined hyperthermia and cisplatin is used to treat OC (Helm, et aI.,
2008). Hyperthermia augments cisplatin-induced cytotoxicity and enhances the
uptake of platinum and platination of DNA (Los, et aI., 1994; van, V, et aI., 1998).
However, complete remission is not attained (Dovern, et aI., 2010). The goal of
this study is to determine if adding sodium arsenite (sodium
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arsenite) to combined cisplatin and hyperthermia will further sensitize cisplatinresistant OC cells to cisplatin.
In vitro studies demonstrate that arsenic induces apoptosis in solid cancer
cells including gastric, colon, pancreatic, lung, prostate and OC (Cui, et aL, 2008;
Murgo, 2001). In vivo, arsenic inhibits the growth of orthotopic metastatic
prostate cancer and peritoneal metastatic OC (Maeda, et aL, 2001; Zhang and
Wang, 2006). Results of combination chemotherapy studies demonstrate that
arsenic sensitizes cancer cells to hyperthermia, radiation, cisplatin, adriamycin,
doxorubicin, and etoposide (Chun, et aL, 2002; Griffin, et aL, 2003; Uslu, et aL,
2000; Wang, et aL, 2001). Arsenic has additive or synergistic effect with cisplatin
following prolonged exposure (Uslu, et aL, 2000; Wang, et aL, 2001; Zhang, et
aL, 2009). Mechanisms of arsenic-induced cell death include formation of
oxidative DNA damage (Nakagawa, et aL, 2002), activation of the Fas pathway
(Kong, et aL, 2005), and inhibition of NER (Nollen, et aL, 2009; Muenyi et aL,
2011) and causation of mitotic catastrophe (McNeely, et aL, 2008a).
In response to DNA damage, p53 is activated and stabilized by upstream
DNA damage sensors. Activated p53 regulates cell cycle arrest, DNA repair and
apoptosis. P53 is often mutated in human cancers (Olivier, et aL, 2002),
especially OC with about 50% of the tumors bearing p53 mutations (Schuijer and
Berns, 2003). The role of p53 in OC response to platinum chemotherapy remains
unclear. Most clinical studies suggest better response to platinum chemotherapy
in patients with p53-mutated tumors than those with wild-type p53 tumors
(Havrilesky, et aL, 2003; Nakayama, et aL, 2003; Okuda, et aL, 2003). Most in
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vitro studies also demonstrate that p53-mutated or p53-null cancer cells are
more sensitive to cisplatin than those expressing wild-type p53 (Hagopian, et aI.,
1999; Havrilesky, et aI., 1995; Yazlovitskaya, et aI., 2001; Metzinger, et aI.,
2006). Therefore, presence of wild-type p53 generally confer resistance to
cisplatin.
Enhanced DNA repair is an important mechanism of cisplatin resistance in
OC cells (Parker, et aI., 1991). XPC is required for platinum-DNA damage repair
(Neher, et aI., 2010). P53 is implicated in platinum-DNA repair because it
transcriptionally regulates XPC (Ford, 2005). Therefore understanding the p53
status of tumors is important in developing personalized chemotherapy to
effectively treat platinum-resistant cancer patients, and interfering with p53
function may suppress DNA repair and sensitize cancer cells to platinum therapy.
The present chapter addresses how the p53 status of OC cells affects
response to new combination chemotherapy of cisplatin, sodium arsenite and
hyperthermia. I show here for the first time that combined sodium arsenite and
hyperthermia sensitize wild-type p53 expressing OC cells to cisplatin by
suppressing XPC and enhancing cellular and DNA platinum accumulation. P53mutated and-null cells were sensitized to cisplatin by hyperthermia only which
involved enhancement of cellular and DNA platinum accumulation.
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HYPOTHESIS
Sodium arsenite and hyperthermia sensitize DC cells to cisplatin by
inhibiting DNA repair and enhancing accumulation of cisplatin.
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MATERIALS AND METHODS

Chemicals
Bovine serum albumin, Tween 20, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5diphenyltetrazolium bromide), RNase A, cisplatin and sodium arsenite were
purchased from Sigma-Aldrich (St. Louis, MO). DMSO was purchased from
Fisher Scientific (Pittsburgh, PA). Stock solutions (cisplatin (1 mg/mL) in
phosphate buffered saline (PBS) and sodium arsenite in water (10 mM)) were
prepared freshly on the day of treatment and filter sterilized (0.22 !-1m) prior to
use. It should be noted that Trisenox® (arsenic trioxide (AS 2 0 3) dissolved in 1 M
NaOH) and sodium arsenite (sodium arsenite) both generate the same oxyanion
[As(OHh] in solution (pharmacological form of arsenic). I used sodium arsenite
for this research because it is readily soluble in water and is stable in water.

Cells and cell culture
Cisplatin-sensitive (A2780) and -resistant (A2780/CP70) human OC cells
were the kind gift of Dr. Eddie Reed (The Mitchell Cancer Institute, University of
South Alabama, Mobile, Alabama). SKOV-3 human OC cells were the kind gift of
Dr. Donald Miller (Department of Medicine, University of Louisville). OVCA 420,
429, 432 and 433 cells were the kind gift of Dr. Zahid Siddik (Department of
Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center,
Houston, Texas). OVCAR-3 cells were purchased from American Type Culture
Collection (Manassas, VA). A2780 and A2780/CP70 and OVCA 420,429,432
and 433 cells were maintained in RPMI 1640 media supplemented with 10% fetal
bovine serum, 100 !-Ig/mL penicillin/streptomycin, 2 mM L-glutamine and 0.2
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units/mL insulin. SKOV-3 cells were maintained in McCoy's 5A media
supplemented with 10% FBS and 100 IJg/mL penicillin/streptomycin. OVCAR-3
cells were maintained in RPMI 1640 media supplemented with 20% fetal bovine
serum, 100 IJg/mL penicillin/streptomycin, 2 mM L-glutamine and 0.01 mg/mL
bovine insulin. Cells were cultured in an atmosphere of 95% humidity and 5%
C02 at 37°C. Cells were passaged twice weekly and replated at a density of 1 X
106 cells/150 mm dish.

Cell Viability assay
The growth inhibitory effects of cisplatin, sodium arsenite and
hyperthermia were evaluated using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5diphenyltetrazolium bromide) cell viability assay (Mosmann, 1983). Briefly, 2500
cells/well were seeded overnight in 96-well plate. Cells were treated with drugs at
3Tor 39°C for 1 h. After treatment, cells were washed twice with PBS and refed
with drug-free media and incubated at 37°C for 5 days prior to assay. Control for
no surviving cells ("blank") was cells treated with 0.1 mg/mL hygromycin B. The
MTT assay evaluates the reduction of yellow tetrazolium salt to insoluble dark
purple formazan crystals by mitochondrial succinate dehydrogenase in cells with
functional mitochondria. The insoluble purple crystals that were formed were
solubilized in DMSO and the absorbance measured at 570 nm. The absorbance
values corresponded to the number of viable cells. Cell viability was calculated
as follows and plotted against concentration of cisplatin.

% cell viability

=

100 x(Mean of triplicate treated samples - Blank)
(Mean of triplicate untreated samples - Blank)
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Data were expressed as means ± SEM of at least 3 independent experiments.
Each experiment was done with triplicate wells for each treatment condition.
P53 and XPC siRNA transfections
One million cells were transfected with 400 nM of either XPC or p53 smart
pool siRNAs (Dharmacon, # L-016040-00 and M-003329-01 respectively), nontargeting control pool (Dharmacon, # 0-001206-13-05), or 1x universal buffer
(Dharmacon, # B-001 050-UB-015) using the Amaxa nucleofector kit V (Lonza,
cat # VCA-1 003, 2.5 mL). After transfection, 2500 cells/well were plated in 96well plates for MTT assay and 1x1 05 cells were plated in 6 cm dishes for western
blot analyses. Cells were incubated at 37°C for 23 h. Cells were then treated
with cisplatin ± 20 11M sodium arsenite at 37°C for 1 h. After treatment, cells
were washed twice with PBS and refed with drug-free media and incubated at 37
°c for 5 days prior to MTT assay. Protein Iysates were collected at 0
(immediately) and 24 h after treatment for western blot analyses.
Western blot analyses
Total cellular Iysates were prepared from treated cells at 0 (immediately),
6, 12, 24, 36,48 and 72 h after treatment. Cells were lysed with cell lysis solution
(10 mM Tris-HCI pH 7.4,1 mM EDTA, 1% sodium dodecyl sulfate, 180 I-Ig/ml
phenylmethylsulphonylfluoride). After removal of debris by centrifugation at
13,000 xg for 45 min, total protein concentration in supernatant was determined
by Bradford assay (Bio-Rad, Hercules, CA), using bovine serum albumin as
standard. Proteins (30-40 I-Ig/Iane) were loaded and resolved by SDSpolyacrylamide gel electrophoresis and electro-transferred to nitrocellulose
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membranes. Membranes were probed with mouse monoclonal antibodies for p53
(Neomarkers, 00-1, dilution 1: 1000), 00B2 (Abcam, # ab51017, dilution 1:50),
XPC (Abcam, # ab6264, dilution 1: 1000), B-actin (Sigma, # A 5441, dilution
1: 10,000), or rabbit polyclonal antibodies for phospho-p53 Ser15 (Cell Signaling
Technology, # 9284, dilution 1:500), XPC (Novus, # NB100-58801, dilution
1:10,000) and XPC (Santa Cruz, A-5, # SC-74411, 1:500). Secondary antibodies
(rabbit anti-mouse IgG, # 81-6120 or goat anti-rabbit, # 81-6120, dilution 1:2500)
conjugated to horseradish peroxidase (Zymed laboratories, Inc. South San
Francisco, CA) were bound to primary antibodies and protein bands detected
using enhanced chemiluminescence (ECl) substrate (Pierce, Rockford, Il)
followed by exposure to Kodak XAR x-ray film. B-actin was used as the loading
control.

G/utathione-S-transferase (GST) activity assay
Cells (2x106 cells/6 cm dish) were treated with 40 IJM cisplatin ± 20 IJM sodium
arsenite at 37 or 39°C for 1 h. Immediately after treatment, cells were washed
twice with phosphate buffered saline and collected in 500 IJl phosphate buffered
saline EOTA (PBSE) by scraping with a rubber policeman. Cells were sonicated
(at 3 pulses for 2 seconds each) using a probe sonicator, centrifuged at 10,000
xg for 15 min at 4°C. The supernatant was collected and stored at -80°C until
use (samples are stable for at least a month). On the day of the assay, 10 mM
glutathione (GSH, Sigma Aldrich, St. louis, MO) in PBSE and 100 mM 1-chloro2,4-dinitrobenzene (CONB, Santa Cruz, # 237329) in ethanol were prepared
fresh (these reagents are stable at room temperature during assay). For total
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glutathione-S-transferase activity determination, 830 IJL PBSE plus 100 IJL GSH
plus 60 IJL protein sample (25 - 50 IJg protein) were transferred into a quartz
cuvette. The cuvette was covered with parafilm wrap and mixed six times. The
parafilm wrap was then removed and the background absorbance read at 340
nm for 1 min using a Varian Cary UV Spectrophotometer (Agilent Technologies,
Palo Alto, CA). Then 10 IJL CONB was added rapidly, reaction mix was mixed six
times and the absorbance for glutathione conjugated CONB (GS-CONB) was
read for 2 min.
(sample)
. . (nmollmln/mg
.
. = (Abs/min
Total GST aCltvlty
protein)
...........
.............. -Abs/min
............(background))
...............
Am nmollmL X mg protein added
The molar extinction coefficient for GS-CONB (Am)

=0.0096 umol-1 cm-1.

Genomic DNA isolation
After treatment, cells were washed twice with PBS and lysed with DNA lysis
buffer (0.5 M Tris-HCI (pH 8.0),20 mM Na2EOTA, 10 mM NaCI, 1% sodium
dodecyl sulfate (SOS), and 0.5 mg/mL proteinase K). Lysed cells were collected
and incubated overnight at 37 cC. The Iysates were mixed with 1/4 volume of
saturated NaCI solution and centrifuged at room temperature for 30 minutes at
500 x g to pellet undigested proteins. The supernatants were collected, mixed
with 2 volumes of 96% ethanol, and inverted several times and kept overnight at
4 aC. The precipitated DNA was recovered, rinsed in 70% ethanol, briefly air
dried to remove excess ethanol, and resuspended in 1X TE buffer (10 mM TrisHCI, pH 7.4 and 1.0 mM Na2EOTA, pH 7.4). DNA was incubated at 3rC with

100 IJgl mL heat-treated RNase A for 3 h, mixed gently with 115 volume of 11 M
ammonium acetate (pH 6.5) and 2 volumes of cold 96% ethanol. DNA was
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allowed to precipitate overnight at -20°C and then recovered, rinsed in 70%
ethanol, briefly dried, and resuspended in 1X TE buffer. DNA was quantified by
A 260 and purity determined by A26o/A28o ratio. DNA was stored at -20°C until use.
Platinum accumulation studies
Cells (1 X 106 /10 cm dish) were treated with cisplatin ± 20 IJM sodium
arsenite at 37 or 39°C for 1 h. The cell monolayers were washed twice with PBS,
harvested and lysed with protein lysis solution. Samples were removed for
protein determination using the bicinchoninic acid (BCA) method according to
manufacturer's instruction (Pierce, Rockford, IL, micro-well plate protocol) (Smith,
et aI., 1985). Then 100 IJL samples of Iysates were transferred to 2 mL acid
washed (washed with 0.1 M nitric acid) centrifuge tubes and Iyphophilized using
FTS systems Flexi-Dry MP (Stone Ridge, NY). Concentrated nitric acid (350 IJL)
was added to every sample and the samples were predigested overnight. After
predigestion, 100 IJL of each sample was transferred into 10 mL acid-washed
microwavable digestion tubes (triplicate for each sample). The samples were
microwave-digested at 150°C for 10 min using an automated focused beam
microwave digestion system (ExplorerTM, CEM, Matthews, NC, USA). Then 1.9
mL of 18 Mohm H20 containing 10 ppb internal standard (SPEX CertiPrep,
Metuchen, NJ) was added into every sample to give final 5% nitric acid. Platinum
was determined using Thermo X Series II Inductively Coupled Plasma Mass
Spectrometry (ICP-MS) instrument (Thermo Fisher Scientific, Waltham, MA)
located at the University of Louisville Center for Regulatory and Environmental
Analytical Metabolomics (CREAM) facility. Concentrated nitric acid was
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processed similarly and used as Blank. Platinum standard (SPEX CertiPrep,
Metuchen, NJ) was used to generate a standard curve. Cellular platinum levels
were expressed as ng platinum/mg protein. Results are the mean of 3 ICP-MS
determinations for each data point from 3 independent experiments.

Statistical analysis
Results are expressed as the mean ± SD of three independent
experiments. Statistical analyses were performed using Microsoft Excel built in
formulas for one-way analysis of variance and student's t-test with significance
level as p < 0.05, n ~ 3.
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RESULTS

Sodium arsenite ± hyperthermia selectively sensitizes wild-type p53
expressing OC cells to cisplatin
P53 regulates DNA repair and is frequently mutated in OC cells. Thus, it is
very important to determine if p53 status will affect response to DNA damaging
chemotherapeutics such as cisplatin. I used wild-type p53 expressing (A2780
(cisplatin-sensitive) and A2780/CP70, OVCA 420, OVCA 429, OVCA 433
(cisplatin-resistant)), p53-null (SKOV-3) and p53 mutated (OVCAR-3 and OVCA
432) human OC cells to determine if the p53 status is an important determinant
of OC cells response to a new combination of cisplatin, sodium arsenite and
hyperthermia. Cells were treated with cisplatin ± 20 IlM sodium arsenite at 37 or
39°C for 1 h. The 20 IlM sodium arsenite I used for all studies was determined to
be non-toxic in A2780 and A2780/CP70 cells when treated for 1 hand MTT
assay five days later (Figure 2).
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Figure 2. Cell viability in response to sodium arsenite. A2780 and
A2780/CP70 cells were treated with the indicated concentrations of sodium
arsenite and incubated at 37°C for 1 h. Cells were then washed twice with PBS
and refed with fresh media and incubated at 37°C . Cell viability MTT assay was
performed five days later. Data are expressed as percentage of untreated control
and plotted as means ± SO of triplicate independent experiments each performed
with triplicate wells.
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Co-treatment of cells with cisplatin plus 20 IlM sodium arsenite or
hyperthermia moderately enhanced cisplatin cytotoxicity in cells expressing wildtype p53 (Figure 3A). However, combined sodium arsenite and hyperthermia
greatly potentiated cisplatin cytotoxicity in wild-type p53 expressing cells. In
contrast, only hyperthermia sensitized p53-null and mutated cells to cisplatin
(Figure 38), combining arsenite with hyperthermia did not further increase
cisplatin sensitivity in cells lacking functional p53 (Figure 38).
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as indicated. B. P53-null (SKOV-3) and mutated (OVCAR-3 and OVCA-432)
cells. Cells were co-treated with the indicated concentrations of cisplatin with
(filled symbols) or without (open symbols) 20 IJM sodium arsenite and incubated
at 37 (circles) or 39°C (triangles) for 1 h. Cells were then washed twice with PBS
and refed with fresh media and incubated for 5 days at 37 cC. Cell viability MTT
assay was performed on day 5. Data are expressed as percentage of untreated
control and plotted as means ± SD of triplicate independent experiments each
performed with triplicate wells. R-values for the best fitting polynomial curves
were all >0.99.
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Sodium arsenite requires functional p53 to sensitize cells to cisplatin
Data in Figure 3 indicate that sodium arsenite sensitizes only wild-type p53
expressing cells to cisplatin. To test whether sodium arsenite requires functional
p53 to sensitize cells to cisplatin, I transfected A2780 and A2780/CP70 cells with
p53 smart pool siRNA, non-targeting control (NSC) or universal buffer (mock).
Western blot data confirmed suppression of p53 at 24 after transfection for
A2780 cells (Figure 4A) and at 24 and 48 h for A2780/CP70 cells (Figure 4C).
MTT cell viability data indicate that suppression of p53 abrogates sodium
arsenite sensitization effect (Figures 48 and 40). Moderate arsenite
sensitization effect on cisplatin was observed in cells transfected with NSC and
mock (Figures 48 and 40). These data indicate that sodium arsenite requires
functional p53 to sensitize cells to cisplatin.
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Figure 4. Cell viability and western blot analysis of cells transfected with

p53 siRNA. A. Western blot analyses of A2780 cells transfected with p53 siRNA,
NSC or mock. B. MTI cell viability assay of A2780 cells transfected with p53
siRNA, NSC or mock. C. Western blot analyses of A2780/CP70 cells transfected
with p53 siRNA, NSC or mock. D. MTT cell viability assay of A2780/CP70 cells
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transfected with p53 siRNA, NSC or mock. A2780 and A2780/CP70 cells were
transfected with p53, smart pool siRNA, non-targeting control (NSC) or mock. At
23 h after transfection, cells were co-treated with the indicated concentrations of
cisplatin with (filled symbols) or without (open symbols) 20 IJM sodium arsenite
for 1h at 37°C. Protein Iysates for western blot analyses were prepared at 24
and 48 h after transfection. Data in panels A and C are representative of 3
independent experiments. Data in panels Band 0 are means ± SO from 3
independent experiments.
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Induction of XPC is p53-dependent
Cisplatin causes DNA damage that is repaired by the nucleotide excision repair
(NER) system. P53 regulates the NER pathway by transcriptionally activating
XPC and DDB2, DNA damage recognition proteins in the global genome repairNER sub-pathway (Ford, 2005). Thus, the p53 dependence of arsenite
sensitization may be related to the role of p53 in DNA repair. Post-translational
modification of p53 is required for its stabilization and activity. P53
phosphorylated on ser392 (p53Ser392P) activates the DNA binding function of
p53 by stabilizing tetramer formation and p53 phosphorylated on ser15
(p53Ser15P) stabilizes p53 (Boehme and Blattner, 2009). Therefore, I determine
the expression of p53Ser15P and p53Ser392P and also DDB2 and XPC
expression in A2780, A2780/CP70, OVCA 420 and SKOV-3 cells 24 h after
cisplatin treatment (Figure 5). P53 and p53Ser15P induction occurred in a
concentration-dependent manner in the wild-type p53 expressing A2780 and
A2780/CP70 cells (Figure 5A and 5B). DDB2 induction in response to cisplatin

treatment was robust in the wild-type p53 expressing cells but modest in p53-null
SKOV-3 cells (Figure 5A and B). Basal XPC expression was observed in both
wild-type p53 expressing and p53 null cells (Figures 5A, 5B and 5C) . However,
induction of XPC occurred only in wild-type p53 expressing A2780, A2780/CP70
and OVCA 420 cells (Figure 5A, 5B and 5C). These results suggest that p53 and
its phosphorylation on Ser15 (p53Ser15P) mediate XPC induction. Robust DDB2
induction in A2780 and A2780/CP70 cells is also regulated by p53 and
p53Ser15P. P53Ser392P was stabilized in OVCA 420 cells (Figure 5C).
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Figure 5
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Figure 5. Expression of DDB2, p53, p53Ser15P, p53Ser392P and XPC in OC
cells after cisplatin treatment A. Western blot determination of DDB2 , p53 ,
p53Ser15P and XPC in A2780 , A2780/CP70 and SKOV-3 cells _B. Densitometry
analysis of DDB2 , p53 , p53Ser15P and XPC for A2780 and A2780/CP70 cells;
DDB2 and XPC for SKOV-3 cells . C. Western blot determination of p53Ser15P ,
p53Ser392P and XPC in OVCA 420 cells . Cells were treated with the indicated
concentrations of cisplatin (CP) at 37 °C for 1 h. After treatment, cells were
washed twice with PBS and incubated in drug-free media for 24 h and protein
Iysates were then prepared . Blots were probed for DDB2 , p53 , p53Ser15P ,
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p53Ser392P and XPC as described in methods. r.,-actin is the loading control.
Blots are representative of 3 independent experiments.
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Sodium arsenite

± hyperthermia sensitizes wild-type p53 expressing cells

to cisplatin by suppressing XPC

Data in Figure 5 suggest that induction of XPC occurs only in wild-type p53
expressing cells. Therefore I predicted that sodium arsenite and/or hyperthermia
sensitize wild-type p53 expressing cells to cisplatin by suppressing XPC. Cells
were treated for 1 h with their respective IC50 cisplatin (A2780
A2780/CP70

=4 11M and

=40 11M (Behrens, et aI., 1987), SKOV-3 =20 11M and OVCA 420 =

45 11M) ± 20 11M sodium arsenite at 37 or 39°C. P53Ser15P and XPC were
induced in a time-dependent manner in A2780, A2780/CP70 and OVCA 420
cells 24 h after cisplatin treatment (Figure 6A, Band C, CP 37°C). P53Ser392P
was induced in a time-dependent manner in OVCA 420 cells (Figure 6C, CP 37
°C). Co-treatment with sodium arsenite suppressed cisplatin-induced XPC in
A2780, A2780/CP70 and OVCA 420 cells (Figure 6A, Band C, CPA 37°C).
Hyperthermia co-treatment did not alter cisplatin-induced XPC in A2780 and
A2780/CP70 cells (Figure 6A and B, CP 39°C), but it suppressed XPC in OVCA
420 cells (Figure 6C, CP 39°C). Combined treatment with sodium arsenite and
hyperthermia suppressed cisplatin-induced XPC in A2780, A2780/CP70 and
OVCA 420 cells (Figure 6A, Band C, CPA 39°C). Sodium arsenite and
hyperthermia did not suppress p53Ser15P. XPC was not induced by cisplatin
over time in p53-null SKOV-3 cells and co-treatment with sodium arsenite ±
hyperthermia did not suppress XPC in these cells (Figure 60).
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Figure 6. Effect of sodium arsenite and hyperthermia on XPC . A, B, C and D
Western blot analyses of XPC , p53Ser15P and p53Ser392P . Cells were treated
with their IC50 cisplatin (CP ; A2780 , 4 !-1M ; A2780/CP70 , 40 !-1M ; SKOV-3, 20 !-1M
and OVCA 420, 45 !-1M) , or CP plus 20 !-1M sodium arsenite (CPA) at 37 or 39 °C
for 1 h. After treatment, cells were washed with PBS and incubated in drug-free
media . Protein Iysates were prepared at the indicated time points for Western
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Blot analysis.

~-actin

and GAPDH are loading controls. Data are representative

blots for 3 independent experiments.
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XPC siRNA sensitizes OC cells to cisplatin
Data in Figure 6 suggest that sodium arsenite suppressed XPC in wild-type p53
expressing cells. In order to better understand the significance of XPC
suppression, I transfected A2780, A2780/CP70 and SKOV-3 cells with XPC
smart pool siRNA, NSC or mock. Suppression of XPC was confirmed by western
blot (Figure 7A). Suppression of XPC moderately sensitized A2780 and
A2780/CP70 cells to cisplatin but had no effect on SKOV-3 cells (Figure 78).
These data suggest that suppression of XPC by sodium arsenite ± hyperthermia
is the mechanism of sensitizing wild-type p53 expressing OC cells to cisplatin.
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Figure 7
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Figure 7. Effect of XPC siRNA on cisplatin cytotoxicity. A. Western blot
analysis of XPC after siRNA transfection . B. MTI cell viability assay of A2780 ,
A2780/CP70 and SKOV-3 cells after siRNA transfection . Cells were transfected
with XPC smart pool siRNA, NSC or mock. At 23 h after transfection , cells were
treated with the indicated concentrations of cisplatin (0) or respective IC50
cisplatin (CP; A2780 , 4 IJM; A2780/CP70, 40 IJM ; SKOV-3, 20 IJM). After
treatment, cells were washed twice with PBS and incubated in drug-free media .

MTI assay was performed 5 days after treatment. Protein Iysates for western
blot analyses were prepared at 24 and 48 h after transfection . Blots are
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representative for 3 independent experiments. Data are means ± SO from 3
independent experiments.
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Effect of cisplatin on ERCC1, XPA and MSH2
Western blot analysis of downstream NER proteins ERCC1 and XPA and the
mismatch repair protein MSH2 revealed that cisplatin did not induce these
proteins in A2780, A2780/CP70 and OVCA 420 cells (Figure 8A, B and C).
However, cisplatin-resistant A2780/CP70 cells expressed higher levels of XPA
and low levels of MSH2 compared to cisplatin sensitive A2780 cells (Figure 8A).
ERCC1 levels were similar in A2780 and A2780/CP70 cells (Figure 8A). ERCC1
and MSH2 were induced in SKOV-3 cells (Figure 8C).
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Figure 8. Expression of ERCC1, MSH2 and XPA in OC cells after cisplatin
treatment. Cells were treated with the indicated concentrations of cisplatin (CP)
at 37 °C for 1 h. After treatment, cells were washed twice with PBS and
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incubated in drug-free media for 24 h and protein Iysates were then prepared.
Blots were probed for ERCC1, MSH2 and XPA as described in methods. Blots
are representative of 2 independent experiments. l3.-actin and GAPDH are
loading controls.
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Sodium arsenite and/or hyperthermia alter ERCC1, XPA and MSH2
expression
Oata in Figure 8A indicate that cisplatin resistance in A2780/CP70 cells is
associated with high levels of XPA and low levels of MSH2. Also, high levels of
XPA were observed in OVCA 420 cells (Figure 88). ERCC1 was induced in
SKOV-3 cells in response to cisplatin treatment (Figure 8C). Therefore, I
performed western blot analysis to determine if sodium arsenite and/or
hyperthermia altered the expression of ERCC1, XPA and MSH2. The data
suggest that sodium arsenite and/or hyperthermia did not suppress ERCC1 or
XPA in A2780, A2780/CP70 and SKOV-3 cells (Figure 9A, 8 and C). MSH2
levels were suppressed by cisplatin ± sodium arsenite at 37 or 39°C in
A2780/CP70 cells (Figure 98), suggesting reduced mismatch repair. Reduced
mismatch repair is associated with increased cisplatin resistance (Fink, et aI.,
1997). Co-treatment with sodium arsenite induced higher levels of ERCC 1 in
OVCA 420 cells (Figure 90, CPA37). ERCC1 and XPA levels decreased over
time in OVCA 420 cells (Figure 90). XPA was completely suppressed by sodium
arsenite plus hyperthermia co-treatment with cisplatin in OVCA 420 cells (Figure
90, CPA39).
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Figure 9. Effect of cisplatin, sodium arsenite and hyperthermia on ERCC1,
XPA and MSH2. Cells were treated with their IC50 cisplatin (CP) (A2780 , 4 I-IM ;
A2780/CP70 , 40 I-IM ; SKOV-3, 20 I-IM; OVCA 420 , 45 I-IM) , or CP plus 20 I-IM
sodium arsenite (CPA) at 37 or 39 °C for 1 h. After treatment, cells were washed
with PBS and incubated in drug-free media . Cell Iysates were prepared at the
indicated time points for Western Blot analyses. UT is untreated control. ~-actin
and GAPDH are loading controls . Data are representative blots from 2
independent experiments.
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Hyperthermia ± sodium arsenite enhance cellular accumulation of cisplatin
Decreased cellular accumulation is an important mechanism of cisplatin
resistance (Parker, et aI., 1991; Cepeda, et aI., 2007). I used inductively coupled
plasma mass spectrometry (ICP-MS) to determine if differential cellular platinum
(platinum) accumulation contributes to resistance and also to determine if sodium
arsenite and hyperthermia alter platinum accumulation (Figure 10). The
concentration response of platinum accumulation (Figure 10A) in the p53 (+)
cisplatin-sensitive cell line (A2780) had a linear correlation of Y

=0.87X + 0.95, R

=0.99. In the resistant cell line (A2780/CP70) the equation was Y =0.38X +
0.55, R =0.99. P53-null SKOV-3 cells had a linear correlation of Y =0.75X +
0.11, R

=0.99. A2780 and SKOV-3 cells accumulated similar levels of platinum

and -2-fold more platinum than A2780/CP70 cells. Hyperthermia alone or
combined with sodium arsenite enhanced platinum accumulation in A2780 cells
(Figure 10B, left panel). Co-treatment with sodium arsenite and hyperthermia
significantly enhanced cellular platinum accumulation in A2780/CP70 cells
(Figure 10B center panel). In contrast, only hyperthermia enhanced cellular
accumulation of platinum in SKOV-3 cells (Figure 10B, right panel).
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Figure 10
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Figure 10. ICP- MS analysis of cellular platinum accumulation and effect of
sodium arsenite and hyperthermia. A. Concentration-dependent accumulation
of platinum in cells. B. Effect of sodium arsenite and hyperthermia on cellular
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platinum accumulation. A2780, A2780/CP70 and SKOV-3 cells were treated with
the indicated cisplatin concentrations for 1 hat 37°C (A) or with 40 ~M cisplatin
with (CPA 37 or CPA 39) or without 20

~M

sodium arsenite (CP 37 or CP 39) at

37 or 39°C for 1 h (8). Cells were harvested immediately after treatment for total
cellular platinum determination. Data are means ± SO from 3 independent
experiments. P<0.05. * compared to CP37, # compared to CPA37 and
compared to CP39.
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Enhanced cellular accumulation of platinum by hyperthermia and sodium
arsenite is not associated with decreased glutathione-S-transferase
acitivity
Increased glutathionylation and export of platinum-GSH and arsenic-GSH
conjugates by the multidrug resistance proteins is a mechanism of resistance to
cisplatin and arsenic respectively (Leslie, et aI., 2004; Stewart, 2007).
Glutathione (GSH) conjugation is mediated by glutathione-S-transferase (GST). I
hypothesized that co-treatment with sodium arsenite, hyperthermia and cisplatin
might decrease GST activity and enable more platinum to accumulate in the
cells. I determined total GST activity as described in Materials and Methods
section. GST activity for all treatment conditions was similar to that of untreated
control (UT) in A2780 and A2780/CP70 cells (Figure 11, left and center panels).
GST activity significantly increased in SKOV-3 cells co-treated with cisplatin,
sodium arsenite and hyperthermia (Figure 11, right panel, CPA 39°C). These
data indicate that decreased GST activity is not a mechanism of enhancement of
cellular platinum accumulation.
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Figure 11
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Figure 11. Total GST activity determination. A2780 , A2780/CP70 and SKOV-3
cells were treated with 40 IlM cisplatin (CP) or CP plus 20 IlM sodium arsenite
(CPA) at 37°C (CP or CPA) or 39°C (CP39 or CPA39) for 1 h. Cells were
harvested immediately after treatment for total GST activity determination. Data
are means ± SO from triplicate biological experiments . P<0 .05.
untreated cells (UT) .
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* compared to

Hyperthermia

± sodium arsenite enhances accumulation of platinum on

DNA

The cytotoxicity of cisplatin is known to depend on its direct interaction
with DNA to form bulky platinum-DNA adducts. I tested the hypothesis that
sodium arsenite and hyperthermia sensitize cells to cisplatin by increasing
platinum (platinum) binding to DNA. Using ICP-MS, I determined platinum bound
to DNA immediately after exposure (0 h) to measure initial platinum binding to
DNA and DNA bound platinum remaining 24 h after treatment to determine repair
of platinum-DNA adducts. I observed that hyperthermia alone or combined with
sodium arsenite significantly increased platinum binding to DNA in A2780 and
A2780/CP70 cells (Figure 12, left and center panels). Retention of platinum on
DNA in A2780 cells was favored by sodium arsenite, hyperthermia or the
combination. In A2780/CP70 cells retention was favored by hyperthermia only. In
SKOV-3 cells, only hyperthermia favored initial binding (0 h) and retention (24 h)
of platinum on DNA (Figure 12, right panel). These data suggest that in the wildtype p53 expressing cells, platinum binding to DNA was favored by both sodium
arsenite and hyperthermia, whereas, in p53-null cells only hyperthermia favored
platinum binding to DNA.
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Figure 12. Determination of sodium arsenite and hyperthermia effect on
DNA-bound platinum. A2780 , A2780/CP70 and SKOV-3 cells were treated with
40 ~M cisplatin for 1 hat 37 or 39°C . Total genomic DNA was isolated at 0
(immediately) and 24 h after treatment for platinum on DNA determination. Data
are means ± SO from 3 independent experiments. P<0.05 ,
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Data in Figure 12 were used to determine platinum-DNA repair as follows:
'
DNA
' - 100 x (pg Ptlf.l9 DNA at 0 h) - (pg Ptlf.lg DNA at ~4 h)
Percen tage pIat Inumrepair (pg Ptlf.lg DNA at 0 h)

A2780/CP70 cells repaired platinum-DNA damage better than A2780 and SKOV3 cells (Figure 13), However, sodium arsenite and hyperthermia did not alter
overall platinum-DNA repair at 24 h after treatment.
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FIGURE 13
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Figure 13. Determination of platinum-DNA repair. A2780 , A2780/CP70 and
SKOV-3 cells were treated with 40 j..lM cisplatin for 1 h at 37 or 39 cC. Total
genomic DNA was isolated at 0 (immediately) and 24 h after treatment for
platinum on DNA determination. Percentage of platinum-DNA repair was
calculated using platinum bound to DNA data in Figure 12. Data are means ± SO
from 3 independent experiments .
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DISCUSSION
The present study was aimed at determining the efficacy and mechanisms
of action of a novel combination of cisplatin, sodium arsenite and hyperthermia in
human OC cells with different p53 status. A panel of wild-type p53 expressing
(A2780 (cisplatin-sensitive) and A2780/CP70, OVCA 420, OVCA 429, OVCA 433
(cisplatin-resistant)) and p53-null (SKOV-3) and p53-mutated (OVCA 432 and
OVCAR-3) human DC cells were used for this study. I showed for the first time
that combining sodium arsenite and hyperthermia sensitizes wild-type p53
expressing cells to dsplatin (Figure 3A). The combination of all three drugs is
more effective than the individual combination. P53-null and p53-mutated cells
were sensitized only by hyperthermia to cisplatin (Figure 38). Suppression of p53
abrogated sodium arsenite sensitization to cisplatin effect (Figure 4), indicating
that the arsenite effect was p53-dependent.
The mechanism of cisplatin cytotoxicity involves DNA damage formation.
However, resistance to cisplatin is a major problem. Mechanisms of cisplatin
resistance are multifactorial and include reduced cellular drug accumulation,
enhanced drug metabolism by glutathionylation, export by multidrug resistance
proteins, enhanced DNA damage tolerance and enhanced DNA repair (Stewart,
et aI., 2007). Enhanced cisplatin-DNA repair by the nucleotide excision repair
pathway (NER) confers resistance to cisplatin (Martin, et aI., 2008). P53
regulates NER by transcriptionally regulating XPC and DD82, critical DNA
damage recognition proteins in global genome repair, a sub-pathway of NER
(GGR-NER) (Ford, 2005). XPC is actively involved in cisplatin-induced DNA

53

damage recognition (Neher, et aI., 2010). Basal expression of XPC was
observed in both wild-type p53 and p53-null cells, consistent with a report that, in
addition to p53, other proteins are involved in regulating basal XPC levels (Lin, et
aI., 2009). However, cisplatin-dependent induction of XPC occurred only in wildtype p53-expressing cells but not in p53-null cells (Figure 4), indicating that
cisplatin-induction of XPC is regulated by p53 in these cells. Co-treatment with
sodium arsenite alone or combined with hyperthermia attenuated cisplatininduced XPC in the wild-type p53 cells (Figure 6A, Band C, CPA 37°C and CPA
39 °C). Suppression of XPC by sodium arsenite ± hyperthermia is a mechanism
of sensitizing wild-type p53 expressing cells to cisplatin because XPC siRNA
moderately sensitizes A2780 and A2780/CP70 cells to cisplatin (Figure 7). Given
that XPC is critical to platinum-DNA damage recognition in GGR-NER,
suppression of XPC could diminish the assembly of the downstream NER repair
complex (Nollen, et aI., 2009) and subsequently decrease DNA repair. Arsenic
has been shown to inhibit p53 DNA binding activity by suppressing p53S392P via
inhibition of CK II (Tang, et aI., 2006). My goal was to investigate whether
p53S392P is required for the transcriptional activation of XPC by p53 and if
arsenic suppression of XPC is via inhibition of p53S392P. However, arsenite did
not inhibit p53Ser392P in OVCA 420 cells, suggesting that arsenite is not acting
by inhibiting CK2.
Decreased cellular accumulation is an important mechanism of cisplatinresistance (Stewart, et aI., 2007). It has been shown previously using atomic
absorption spectroscopy that A2780 cells accumulate -2-fold more cellular
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platinum than A2780/CP70 cells (Parker, et aI., 1991). Here, I used a more
sensitive analytical technique (lCP-MS) and showed that A2780 cells accumulate
-2.3 fold more platinum than A2780/CP70 cells (Figure 10A), consistent with the
earlier platinum measurements. Cisplatin-resistance in SKOV-3 cells has been
linked partially to decreased cellular platinum accumulation (Mistry, et aI., 1992).
However, a comparative cellular cisplatin accumulation study by Johnson et al
indicated that A2780 and SKOV-3 cells accumulated similar levels of platinum
during 4 h incubation with equimolar concentrations of cisplatin (Johnson, et aI.,
1997). In the current study, I showed that A2780 and SKOV-3 cells accumulated
similar level of cellular platinum when treated with 40 11M cisplatin; similar to
previous findings by Johnson et al. Co-treatment of A2780 cells with
hyperthermia ± sodium arsenite significantly enhanced cellular accumulation of
platinum. Combined sodium arsenite and hyperthermia significantly enhanced
platinum accumulation in A2780/CP70 cells (Figure 108). Consistent with my
findings that only hyperthermia sensitized SKOV-3 cells to cisplatin, I also
observed that only hyperthermia increased cellular platinum accumulation in
these cells (Figures 108). Therefore, increasing cellular platinum accumulation is
a mechanism by which sodium arsenite and hyperthermia are sensitizing wildtype p53 expressing cells to cisplatin. Enhanced platinum accumulation is not
associated with decreased GST activity (Figure 11).
Reduced platinum bound to DNA contributes to cisplatin resistance
(Parker, et aI., 1991). When A2780 and A2780/CP70 cells were treated with 40
11M cisplatin, wild-type p53 A2780 (cisplatin-sensitive) and p53-null SKOV-3
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(cisplatin-resistant) cells accumulated similar amounts of platinum on DNA
(Figure 12A), contrary to previous findings by Johnson et al. (Johnson, et aI.,
1997). The observed difference in amount of platinum bound to DNA between my
study and that of Johnson et al could be due to differences in drug exposure and
platinum determination times. Johnson et al treated cells for 4 h and assayed for
platinum at 0 (immediately after treatment) and 8 h after treatment, whereas, I did
a 1 h exposure and determined platinum levels at 0 and 24 h after treatment. My
data suggest that cisplatin-resistance in SKOV-3 cells is not due to decreased
platinum bound to DNA. However, cisplatin-resistance in wild-type p53
A2780/CP70 cells is due to decreased platinum bound to DNA, consistent with
previous findings (Parker, et aI., 1991). Hyperthermia alone or combined with
sodium arsenite significantly increased initial (0 h) platinum bound to DNA in both
A2780 and A2780/CP70 cells (Figure 128). Meanwhile, platinum retention (24 h)
on DNA was favored by sodium arsenite, hyperthermia or the combined
treatment in A2780 cells. Retention was favored by hyperthermia in A2780/CP70
cells (Figure 128). Therefore, increased accumulation of platinum bound to DNA
is a mechanism by which sodium arsenite and hyperthermia are sensitizing wildtype p53 cells to cisplatin. In p53-null SKOV-3 cells, only hyperthermia increased
platinum bound to DNA accumulation (Figure 128). Sodium arsenite and
hyperthermia did not alter platinum-DNA damage repair (Figure 13).
In summary, I have shown for the first time that combining sodium arsenite
and hyperthermia with cisplatin sensitizes wild-type p53 expressing human OC
cells to cisplatin by attenuating XPC induction in response to cisplatin and
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enhancing cellular and DNA bound platinum accumulation. The combination of
cisplatin, sodium arsenite and hyperthermia works better than the individual
combinations because each drug has a different mechanism of action. Further
studies using in vivo cancer models are necessary to determine whether this
combination therapy may improve clinical outcomes.
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CHAPTER 3
SODIUM ARSENITE AND HYPERTHERMIA MODULATE CISPLATIN-DNA
DAMAGE RESPONSES AND ENHANCE PLATINUM ACCUMULATION IN
MURINE METASTATIC OC XENOGRAFT AFTER HYPERTHERMIC
INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
(This chapter has been published as Muenyi et aL, JOR, 2011.)
INTRODUCTION
Epithelial OC (OC) is the leading cause of gynecological cancer death in
the U.S. (Jemal, et aL, 2010). Most women are diagnosed only after peritoneal
dissemination has occurred. The standard treatment for patients with OC is
cytoreductive surgery (CRS) followed by intravenous platinum-taxane
chemotherapy (Armstrong, et aL, 2006). Even though initially effective, relapse
from residual disease and/or drug resistant cancer reduces the 5-year survival
rate to about 20% (Ozols, 2005). Despite research efforts to improve on
platinum-based chemotherapy, or to develop new drugs against OC, most
patients still die from metastatic disease. Since metastatic OC is usually confined
in the peritoneal cavity, it makes theoretical sense to deliver chemotherapy
intraperitoneally rather than intravenously since higher levels of drug can be
delivered to the disease site by that route (Markman, 2001; van, V, et aL, 1998).
In response to three large randomized clinical trials showing benefit to
incorporating intraperitoneal (lP) delivery in OC, the National Cancer Institute
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issued a clinical announcement recommending that patients with small volume
disease at the end of frontline surgery be offered the opportunity to receive IP
chemotherapy (Trimble and Christian, 2008). Adding hyperthermia to
chemotherapy agents delivered intraperitoneally (HIPEC) could improve outcome
(Helm, 2009; Yang, et aI., 2010; Dovern, et aI., 2010).
Cisplatin is a DNA damaging chemotherapeutic used to treat solid tumors
including DC. However, resistance to cisplatin limits clinical success (Stewart, et
aI., 2007). Since platinum-containing chemotherapy drugs remain the major
weapon against DC, improving their efficacy could have a great impact on
mortality. The combination of hyperthermia with cisplatin administered
intraperitoneally (HIPEC) has been reported for the treatment of DC (Helm, et aI.,
2008). However, complete remission is not achieved with HIPEC therapy
(Dovern, et aI., 2010). Adding arsenic could potentially sensitize cancer cells to
cisplatin and hyperthermia (Helm and States, 2009; Wang, et aI., 2001; Griffin, et
aI., 2003). In vivo studies also show that arsenic inhibits the growth of orthotopic
metastatic prostate cancer and peritoneal metastatic DC (Maeda, et aI., 2001;
Zhang and Wang, 2006). The mechanism of arsenic-induced cell death in vitro is
suggested to include formation of oxidative DNA damage (Nakagawa, et aI.,
2002), activation of the Fas pathway (Kong, et aI., 2005), inhibition of DNA repair
(Hartwig, et aI., 1997; Nollen, et aI., 2009), and causation of mitotic arrest and
induction of apoptosis in the mitotic cells (McNeely, et aI., 2008a; Taylor, et aI.,
2008).
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Enhanced repair of platinum-DNA damage by the nucleotide excision
repair (NER) pathway (Earley and Turchi, 2010), decreased mismatch repair
(MMR) (Fink, et aI., 1997) and reduced accumulation contribute to cisplatin
resistance (Parker, et aI., 1991). Adding arsenic to cisplatin and hyperthermia
could potentially decrease cisplatin resistance by decreasing NER, enhancing
MMR and increasing accumulation. Arsenic and cisplatin are detoxified by
glutathionylation and exported by multidrug resistant family transport pumps
(Leslie, et aI., 2004; Stewart, 2007), suggesting a potential for competition for the
detoxification pathway if arsenic and cisplatin are used in combination. This
competition might enhance cisplatin accumulation in tumors.
The goal of this study is to determine how sodium arsenite and
hyperthermia modulate mechanisms of cisplatin resistance in vivo. We
developed murine models of HIPEC treatment and metastatic human DC to
investigate if sodium arsenite and hyperthermia alter the expression of DNA
repair proteins, tumor platinum levels and systemic distribution of platinum. I
show that sodium arsenite and hyperthermia either as single agents or in
combination reverse key DNA repair proteins (XPA, XPC and MSH2) responsible
for cisplatin resistance and also enhanced tumor platinum uptake suggesting
decreased platinum detoxification. Sodium arsenite and hyperthermia did not
alter systemic platinum distribution.
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HYPOTHESIS
Sodium arsenite and hyperthermia modulate cisplatin-induced DNA
damage responses and enhance platinum accumulation in metastatic tumors.
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MATERIAL AND METHODS
Animals
Female NCr athymic nude mice (7 - 9 weeks old), were purchased from
Taconic (Cambridge City, IN). Animals were kept in a temperature-controlled
room on a 12 h light-dark schedule. The animals were maintained in cages with
paper filter covers under controlled atmospheric conditions. Cages, covers,
bedding, food, and water were changed and sterilized weekly. Animals were fed
autoclaved animal chow diet and water. All procedures were performed under
sterile conditions. This experiment was approved by the Institutional Animal Care
and Use Committee of the University of Louisville in an AALAC approved facility
in accordance with all regulatory guidelines.
Establishment of intraperitoneal metastatic ovarian tumors in mice
A2780/CP70 cell suspension (1x10 6 cells in 500 IJL of serum-free RPMI
1640 media) was injected into the peritoneum of anesthetized mice using an 18gauge needle. The needle was flushed with 500 IJL physiological saline. The
abdomen of injected animals was massaged to ensure even distribution of cells.
By 3 - 4 weeks after injection, the mice had developed multiple small
disseminated intraperitoneal tumors (1 - 7 mm) (Figure 14). Tumors were
monitored by microCT scanning in the Brown Cancer Center Small Animal
Imaging Facility.
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Figure 14

Figure 14. Mouse with multiple small intraperitoneal tumors. A. MicroCT
scan of tumors in live mouse. B. Direct visualization of tumors at necropsy of
mouse . Three tumors are denoted by arrow in panels A and B .
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Intraperitoneal chemotherapy
Tumor-bearing mice were anesthetized with 3% isoflurane in an inhalation
chamber and maintained on 1% isoflurane during surgery. Incisions (-0.5 cm)
were made on both sides of the lower abdominal wall allowing entry into the
peritoneal cavity (Figure 15). Inflow and outflow tubes were inserted into the
peritoneal cavity and secured with skin sutures. The tubes were connected to a
bag containing 100 mL normal saline with added cisplatin (3 mg/kg body weight
(BW)) ± sodium arsenite (26 mg/kg BW) and cefazolin (0.01 mg/mL). (The dose
of cisplatin used for this study was determined from human dose of cisplatin (100
mg/m 2 ) administered intravenously to a 70 kg (body surface area

=1.87 m2)

(Reagan-Shaw, et aI., 2008) cancer patient and sodium arsenite dose was
calculated from a single daily dose of Trisenox (0.15 mg/kg/day) administered
intravenously to a 70 kg acute promyelocytic leukemia patient. The underlying
assumption in the calculations is that the drugs are mixed in 2 L saline solution
for HIPEC therapy in humans). The saline bag was submerged in a water bath to
maintain the perfusate temperature at either 37 or 43°C. Perfusion was
performed at a rate of 3 mLlmin for 60 min using a Masterflex pump (ColePalmer Instrument Co, Cat # 07524-50). The inflow and outflow temperatures
were monitored by thermocouple probes with temperature maintained within 1°C.
The core temperature of the animals was monitored using an anal temperature
probe and maintained using a heating pad and heat lamp. After 60 min perfusion,
most of the perfusate in the peritoneum was sucked out using sterile cotton balls
with a light abdominal massage. Wounds were sutured closed and animals were
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injected intraperitoneally with 1 mL physiological saline containing 0.01 mg
ketoprofen for pain. Mice were kept in warm cages (single mouse/cage) and
monitored for recovery and discomfort. Immediately (0 h) and 24 h after
perfusion, mice were euthanized and tumors, kidneys, liver, spleen, heart and
brain were dissected and snap frozen in liquid nitrogen and stored at -80°C until
use.
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Figure 15

A.

Figure 15. Murine hyperthermic intraperitoneal chemotherapy model. A.
Drawing of tumor bearing mouse undergoing HIPEC. Depicted are inlet (a) and
outlet (b) ports and anal temperature probe (c) to monitor internal temperature of
mouse during perfusion . B. Photograph showing perfusion pump (a) ,
temperature monitor (b) , flow tubes (c) and heating bath (d) . Mice were perfused
for 1 h at the rate of 3 mLlmin with cisplatin (3 mg/kg) ± sodium arsenite (26
mg/kg) at 37 or 43°C .
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Western blot analysis
Tumors of - 3-5 mm in diameter were homogenized in protein lysis
solution (10 mM Tris-HCI pH 7.4,1 mM EDTA, 1% sodium dodecyl sulfate, 180
IJg/ml phenylmethylsulphonylfluoride) using a tissue grinder. After removal of
debris by centrifugation (45 min, 14,000 x g), total protein concentration in
supernatant was determined by bicinchoninic acid (BCA) method according to
manufacturer's instructions (Pierce, Rockford, IL, micro-well plate protocol)
(Smith, et aI., 1985). Fifteen IJg protein samples were resolved by SDSpolyacrylamide gel electrophoresis and electro-transferred to nitrocellulose
membranes. Membranes were probed with antibodies to XPA (Neomarkers, MS650-P1, dilution 1: 1000), XPC (Novus, # ab6264, dilution 1: 10,000), GAPDH
(Sigma, #A 5441, dilution 1:10,000), p53 (DO-1, Cell Signaling Technology, #
9284, dilution 1: 1000), MSH2 (Santa Cruz, # SC-494, dilution 1: 1000), and
ERCC1 (Santa Cruz, # SC-10785, dilution 1:1000). Secondary antibodies (rabbit
anti-mouse IgG, # 81-6120 or goat anti-rabbit, # 81-6120, dilutions 1:2500)
conjugated to horseradish peroxidase (Zymed Laboratories, Inc. South San
Francisco, CA) were bound to primary antibodies and protein bands detected
using enhanced chemiluminescence (ECL) substrate (Pierce, Rockford, IL).
GAPDH was used as the loading control. Films were scanned with a Molecular
Dynamics Personal Densitometer SI (Molecular Dynamics, Sunnyvale, CA) and
analyzed with ImageQuaNT software (Molecular Dynamics) to determine band
density.
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ICP-MS analysis
Samples of tumor homogenates were Iyphophilized using Heto vacuum
centrifuge (ATR, laurel, MO) and 350 III concentrated nitric acid was added to
each sample. Wet weight of brain, heart, spleen, liver and kidney was recorded
and concentrated nitric acid (350 - 500 IJl) was added to samples. Samples were
predigested overnight, and then 100 IJl of each dissolved sample was
transferred into 10 ml acid washed microwavable digestion tubes (triplicate for
each sample). The samples were microwave-digested at 150°C for 10 min using
an automated focused beam microwave digestion system (ExplorerTM, CEM,
Matthews, NC, USA). After digestion, 1.9 ml of 18 Mohm H2 0 containing 10 ppb
internal standard (SPEX CertiPrep, Metuchen, NJ) was added into every sample
to give final 5% nitric acid and ICP-MS analyses was performed using Thermo X
Series II ICP-MS (Thermo Fisher Scientific, Waltham, MA) at the University of
louisville Center for Regulatory and Environmental Analytical Metabolomics
facility. Concentrated nitric acid was processed similarly as blank. Platinum
standard (SPEX CertiPrep, Metuchen, NJ) was used to generate a standard
curve. Platinum and arsenic levels in tumors and tissues were expressed as ng
metallmg protein and ng metallmg wet weight respectively. Results are
presented as the means of three ICP-MS determinations for each data point ±
SO from 3 individual mice.
Immunocytochemistry
Cells (1 x 105 ) were plated on poly-O-Iysine coated coverslips (BO
Biosciences) in a 24-well plate and allowed to acclimate for 24 h. Cells were then
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treated with 40 IJM cisplatin for 1 h. After treatment, cells were washed twice with
PBS and incubated in drug-free media for 24 h. Cells were fixed in ice-cold
acetone for 10 min at room temperature and washed twice with ice cold PBS and
samples incubated for 10 min with PBS containing 0.25% Triton X-100 (PBST).
Cells were then washed with PBS three times for 5 min and incubated in 3%
hydrogen peroxide for 30 min to quench endogenous peroxidase. Cells were
washed three times with PBS and incubated in 1% BSA in PBST for 30 min to
block unspecific binding of the antibodies. Cells were incubated overnight at 4°C
in primary antibodies (1 :200 dilution in PBST containing 1% BSA). The primary
antibodies used were XPA (Neomarkers, MS-650-P1), XPC (H-300, SantaCruz
Biotechnology, # sc-30156), p53 (00-1, Cell Signaling Technology, # 9284),
MSH2 (Santa Cruz, # SC-494) and ERCC1 (Santa Cruz, # SC-10785). After
incubation, the primary antibody solution was decanted and cells were washed
three times with PBS for 5 min each wash. Cells were incubated with secondary
antibodies (rabbit anti-mouse IgG, # 81-6120 or goat anti-rabbit, # 81-6120,
dilution 1:200 in PBST containing 1% BSA) conjugated to horseradish
peroxidase (Zymed Laboratories, Inc. South San Francisco, CA) for 1 h at room
temperature. Secondary antibody solution was decanted and cells were washed
three times with PBS for 5 min. Cells were stained with 3,3'-diaminobenzidine
(DAB) substrate solution by incubating cells in 200 IJL premixed DAB solution
(mix 30 IJL (one drop) of the DAB liquid chromogen solution to 2 mL of the DAB
liquid buffer solution (Sigma, # 0 3939)) for 10 min. DAB solution was removed
and cells rinsed briefly with PBS. Cells were counterstained with 20% Wright
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Giemsa solution for 1 min. Coverslips were mounted on microscope slides using
a drop of permount mounting medium. Slides were viewed under a Nikon Eclipse
E600 Microscope (Fryer Company Inc, Scientific Instruments, Cincinnati OH
45240) and pictures taken using MetaMorph software (Universal Imaging
Corporation). DAB-positive cells were counted per 1000 cells using MetaMorph
software.
Statistical analysis
Statistical analyses were performed using wilcoxon rank sum test with
significance set as p < 0.05, n

~

3.
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RESULTS
Murine intraperitoneal chemotherapy model
Multiple disseminated tumors were established in the peritoneal cavity of
nude mice as described in Materials and Methods. Mice were scanned using
microCT scan to determine the location and estimate the size of tumors (Figure
14A). This was confirmed upon necropsy (Figure 148).
Tumor bearing mice were treated by peritoneal lavage for 1 h with
cisplatin ± sodium arsenite at 37°C (normothermia) or 43 °C (hyperthermia)
(Figure 15A and 8) as described in Materials and Methods.
During treatment, the required inflow temperature was reached within 2-5
min after the start of perfusion. Inflow, outflow and rectal temperatures were
recorded every 15 min and remained stable within 1 °C throughout the 60 min
perfusion (Table 1).
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Table 1: Inflow, outflow and body temperatures of mouse during intraperitoneal
perfusion.
Inflow
temperature

Outflow
temperature

Body
temperature

37.4 ±1.1 °C

36.4 ± 0.8 °C

35.5 ± 1.0 °C

43.0 ± 0.7 °C

39.7 ± 0.6 °C

36.3 ± 2.1 °C

Mice were perfused for 1 h with cisplatin (CP/37; CP/43) or cisplatin + sodium
arsenite (CPAl37; CPAl43) at 37 or 43°C respectively. Inflow, outflow and body
temperatures were recorded every 15 min. Data are presented as means ± SD of
readings taken from five mice.
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Platinum and arsenic accumulation and retention in metastatic tumors
I determined platinum and arsenic accumulation in tumors immediately (0
h) and 24 h after perfusion using ICP-MS. platinum and arsenic accumulated in
tumors during treatment (0 h) and generally decreased after treatment (24 h),
compared with the untreated control (Figure 16). Co-treatment with sodium
arsenite and cisplatin at 37°C (CPAl37) or 43°C (CPAl43) caused significantly
more platinum to accumulate in tumors. By 24 h after perfusion, tumor platinum
levels for CPAl37 and CPAl43 treatment conditions decreased to levels similar to

CP/37. Hyperthermia did not increase tumor platinum levels nor alter platinum
retention in tumors 24 h after treatment. More arsenic initially accumulated in
tumors when co-treated with cisplatin and sodium arsenite at 37°C (CPAl37)
than with hyperthermia treatment (CPAl43). Arsenic decreased to similar levels
at 24 h.
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Figure 16
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Figure 16. Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
determination of platinum and arsenic in tumors. Mice were perfused for 1 h
with cisplatin (CP/37 ; CP/43) or cisplatin plus sodium arsenite at 37 or 43°C
respectively (CPAl37; CPAl43). Tumors from untreated (UT) and treated mice
were harvested at 0 and 24 h after treatment. Tumors were homogenized and
samples of the homogenate were analyzed for protein concentration by BCA or
digested in nitric acid for ICP-MS analysis for platinum and arsenic. Data are
presented as means ± SEM of ~3 tumors each from different mice. Statistical
analysis was performed using wilcoxon rank sum test. P < 0.05 , N ~ 3: #
than 0 h partner, :t:

=lower

=higher than CP/37 at 0 hand CP/43 at 0 h, 11 =higher than

CPAl43 °C at 0 h.
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Effect of cisplatin, arsenic and hyperthermia on DNA repair protein
expression
Cisplatin causes bulky DNA damage that is repaired mostly by the
nucleotide excision repair system (NER). Cellular response to cisplatin-DNA
damage involves the induction of DNA repair proteins to initiate DNA repair
(Cepeda, et aI., 2007). I determined if sodium arsenite and hyperthermia
modulated the expression of XPC, a platinum-DNA damage recognition protein in
global genome repair (GGR) (Neher, et aI., 2010) sub pathway of NER, and of
ERCC1 and XPA, downstream NER proteins that have been implicated in
cisplatin resistance (Dabholkar, et aI., 1994). I also determined the expression of
p53, which is involved in the activation of the GGR pathway by transcriptionally
activating XPC (Ford, 2005). In addition to NER, decreased mismatch repair
(MMR) has been implicated in cisplatin resistance (Fink, et aI., 1997; Jensen, et
aI., 2008). Thus, we also investigated the expression of MSH2, an important
MMR DNA damage recognition protein. Western blot analysis of p53, XPC, XPA,
ERCC1and MSH2 revealed mouse-to-mouse and tumor-to-tumor variabilities
(Figure 17A). Some tumors failed to express the protein of interest while others
either expressed high, moderate or very low levels of the proteins. I determined
band intensities for the expressed proteins by scanning the films using a
Molecular Dynamics Personal Densitometer SI (Molecular Dynamics, Sunnyvale,
CA) and analyzing bands of interest using ImageQuaNT software (Molecular
Dynamics). Each protein value was normalized to its respective GAPDH (loading
control) value. Data were further normalized to untreated control (Figure 178).
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Tumors that failed to express the protein of interest were not considered in the
densitometry analyses. P53 (Figure 17B, panel a) and XPC (Figure 17B, panel b)
were significantly induced during treatment (0 h) by cisplatin at 37 DC (CP/37) or
43 DC (CP/43) and cisplatin plus arsenite at 43 DC (CPAl43). P53 significantly
decreased at 24 h after treatment with CPAl43 (Figure 17B, panel a). XPC
decreased at 24 h after perfusion with both CP/43 and CPAl43 treatments
(Figure 17B, panel b). P53 (Figure 17B, panel a) and XPC (Figure 17B, panel b)
did not significantly increase during (0 h) and after (24 h) peritoneal lavage with
sodium arsenite and cisplatin co-treatment at 37 DC (CPAl37). XPA (Figure 17B,
panel c) was significantly induced during (0 h) and 24 h after perfusion with
CP/37, CPAl37 and CPAl43 but not with CP/43. ERCC1 remained generally low
for all treatment conditions except with CPAl37 (Figure 17B, panel d). The
suppression of MSH2 by CP/37 and CP/43 treatments was not seen in tumors
co-treated with arsenite (CPAl37, CPAl43) (Figure 17B, panel e).
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Figure 17. DNA repair protein expression in tumors. A. Western blot
determination of p5:~, XPC, XPA, ERCC1 and MSH2 in tumors. GAPDH is
loading control. B. Densitometry analyses of (a) p53, (b) XPC, (c) XPA, (d)
ERCC1 and (e) MSH2 normalized to GAPDH loading control and untreated
tumors. Mice were perfused for 1 h with cisplatin (CP/37; CP/43) or cisplatin plus
sodium arsenite (CPAl37; CPAl43) at 37 or 43°C respectively. Tumors from
untreated (UT) mice and treated mice were harvested at 0 and 24 h after
treatment. Protein extracts were prepared from the tumors and 20 tJg loaded per
lane for SDS-PAGE.. Data are presented as means ± SD of ~5 tumors each from
different mice. Statistical analysis was performed using wilcoxon rank sum test. P
< 0.05, N

~

5. # = compared to 0 h partner, *= compared to UT.
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Expression of P53, XPA and MSH2 in OC cells
Western blot determination of P53, XPC, XPA, ERCC1 and MSH2 in
metastatic tumors revealed that some tumors failed to express p53 (6%), XPC
(3%), XPA (8%), ERCC1 (40%) and MSH2 (9%) (Figure 17A). Failure to express
these proteins could be an inherent feature of the cells that were used to
establish the tumors or due to mutations and alteration of genes during tumor
development that could result in lack of protein expression. I therefore performed
immunocytochemistry studies using A2780/CP70 cells to determine expression
of P53, XPA and MSH2 in these cells (Figure 18A). Immunocytochemistry data
revealed that 25% of cells do not express p53 as evident by lack of 3,3'diaminobenzidine (DAB) brown staining and -3% and 60% of cells did not stain
positive for XPA and MSH2 respectively (Figure 18B). Full-length western blots
for XPC and ERCC1 had several non-specific bands in addition to the band of
interest (data not shown) making it impossible to perform Immunocytochemistry
with specificity for these proteins.
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Figure 18. Immunocytochemical determination of p53, XPA and MSH2
expression in OC cells. A. A2780/CP70 cells were treated for 1 h with 40

~M

cisplatin. Cells were washed and incubated in drug-free media for 24 hand
immunohistochemistry was performed. Representative pictures at 20x
magnification of cells for secondary antibody only control (a), p53 (b) , XPA (c)
and MSH2 (d) . B. Plot of percentage of 3,3'-diaminobenzidine (DAB)-positive
cells. Data are single biological experiment performed in duplicate. Four different
fields were counted per coverslip .
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Platinum and arsenic biodistribution in somatic tissues
The clinical use of anticancer chemotherapeutic agents is limited by
adverse toxicities. For cisplatin, these include toxicity to the kidney, peripheral
nerves, liver, heart, bone marrow and brain (Hartmann and Lipp, 2003; GessonPaute, et aI., 2008). Clinical use of arsenic is known to cause liver, kidney and
neurological damage, cardiovascular and gastro-intestinal toxicity, anemia and
leucopenia (Senkus and Jassem, 2010; Emadi and Gore, 2010; Au and Kwong,
2008). Therefore, I determined cisplatin and arsenic accumulation in mouse
tissues including kidney, liver, heart, spleen and brain (Figures 19A and 8).
Samples were prepared as described in Methods. During perfusion, platinum
accumulated in all tissues examined regardless of the treatment condition, in the
order: kidney> liver

=spleen> heart> brain. At 24 h after perfusion, significant

decrease of platinum was observed in the kidney for all treatment conditions. The
combination treatment (CPAl43) favored the removal of platinum from the liver,
spleen and heart at 24 h after perfusion. Arsenic also significantly accumulated in
all the tissues examined, in the order: liver> kidney

=spleen> heart> brain and

it significantly decreased in all tissues by 24 h after perfusion.
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Figure 19
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Figure 19. Platinum and arsenic accumulation in somatic tissues. Mice were
perfused for 1 h with cisplatin (CP/37 ; CP/43) or cisplatin plus sodium arsenite
(CPAl37; CPAl43) at 37 or 43°C respectively. Tissues from untreated (UT) and
treated mice were harvested at 0 and 24 h after treatment. Tissue samples were
weighed and digested in nitric acid for ICP-MS analysis for platinum (A) and
arsenic (8) . Data are presented as means ± SD of triplicate samples each from
different mice. Statistical analysis was performed using wilcoxon rank sum test. P
< 0.05 , N

=3. # =compared to 0 h partner.
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DISCUSSION
Although the platinum analogues (cisplatin and carboplatin) are at the
forefront of combination chemotherapy for OC, acquired or inherent resistance
limits clinical success. In the current study, I used metastatic OC xenograft in
nude mice to investigate how sodium arsenite and hyperthermia modulate
response to cisplatin in vivo. I focused on three key mechanisms of cisplatin
resistance: enhanced NER, diminished MMR and decreased platinum
accumulation. My data suggest that cisplatin induces resistant phenotype in
metastatic tumors by inducing XPC and XPA and suppressing MSH2. Sodium
arsenite alone or combined with hyperthermia inhibits mechanisms of cisplatin
resistance by suppressing XPC induction, maintaining higher levels of MSH2 and
increasing tumor uptake of cisplatin.
Decreased platinum accumulation is an important mechanism of cisplatin
resistance. Hyperthermia has been reported to increase both cellular and DNA
bound platinum levels in vitro. However, in vivo data remain controversial. Los et
al used rats bearing metastatic colon cancer to show that hyperthermia
suppressed tumor growth by increasing platinum accumulation in tumors (Los, et
aI., 1994). Zeamari et al used a similar colon cancer xenograft model in rats and
reported that hyperthermia did not increase tumor platinum levels (Zeamari, et
aI., 2003). Similar to Zeamari, I observed that hyperthermia does not increase
platinum accumulation in tumors. The observed discrepancies with Los et al
could be due to differences on how HIPEC was performed. Los et al injected
hyperthermic cisplatin intraperitoneally; whereas I and Zeamari et al performed
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peritoneal lavage similar to what is done clinically. Unlike hyperthermia, I
observed that sodium arsenite at 37 or 43°C increased initial tumor platinum
levels. Since arsenic and cisplatin are detoxified by glutathionylation and export
by the multidrug resistant family proteins, potential competition for the
detoxification/export pathways might have resulted in more platinum
accumulating in the tumors when cisplatin is co-administered with sodium
arsenite.
Cisplatin is a DNA damaging agent and p53 is implicated in platinum-DNA
damage response (Ford, 2005). P53 is frequently mutated in OC (Berchuck, et
aI., 1994). The p53 phenotype of A2780/CP70 cells remains controversial. Some
studies have demonstrated that A2780/CP70 cells have non-functional p53
(Jones, et aI., 1998; Lu, et aI., 2001), while other studies have shown that these
cells have wild type p53 (Brown, et aI., 1993; Yazlovitskaya, et aI., 2001). My
data indicate that A2780/CP70 cell population is heterogeneous: -75% of cells
express wild type p53 and -25% are p53 null (Figure 18). In addition, 6% of the
tumors derived from A2780/CP70 are p53 null (Figure 17A). My in vitro data also
demonstrate the induction of p53 target genes CDKN1A, XPC and DDB2 in
A2780/CP70 cells (Figures 5 and 25), which strongly suggests that a large
fraction of these cells have wild type p53. The observed heterogeneity might
have resulted from mutations and alterations that occur during serial propagation
of cells in culture leading to cell line drift (Hughes, et aI., 2007). The observed
heterogeneity may impact response to chemotherapy and result in treatment
failures because p53 wild type and null cells will respond differently to
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chemotherapy especially DNA damaging agents such as cisplatin. This
heterogeneity explains why targeting master regulators such as p53 or AKT in
cancer cells has not been successful (Zeimet and Marth, 2003; Engelman, 2009).
Therefore, combination chemotherapy such as cisplatin, sodium arsenite and
hyperthermia with different mechanisms of action might be more beneficial than
using a single drug to target a single protein or pathway.
Cisplatin predominantly forms intrastrand DNA crosslinks that are repaired
by the nucleotide excision repair (NER) system. There are two sub-pathways of
NER; transcription coupled repair (TCR) which removes damage from actively
transcribing DNA and global genome repair (GGR) which removes lesions from
the entire genome (Martin, et aL, 2008). These two pathways differ only in the
proteins that are involved in damage recognition. In TCR, CSA and CSB along
with RNA pol II recognize damage, whereas in GGR, XPC and DDB2 are
important for lesion recognition. XPC is actively involved in the recognition and
initiation of cisplatin-DNA damage repair in GGR (Earley and Turchi, 2010;
Neher, et aL, 2010). Arsenic has been shown to inhibit NER by inhibiting XPC
expression (Nollen, et aL, 2009). In the current study, I observed that P53 and
XPC were induced by cisplatin. However, sodium arsenite alone or in
combination with hyperthermia prevented the induction of p53 and XPC by
cisplatin (Figure 178, panels a and b). Since p53 is known to transcriptionally
induce XPC (Ford, 2005), my data suggest that sodium arsenite ± hyperthermia
might be inhibiting p53, which in turn might be suppressing XPC induction.
Suppression of XPC will potentially sensitize tumors to cisplatin because my in
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vitro data indicate that inhibition of XPC using siRNA sensitizes OC cells to
cisplatin (Figure 7). Therefore, the suppression of XPC could potentially sensitize
tumors to cisplatin in a similar fashion. Following DNA damage recognition,
downstream DNA repair proteins (XPA, RPA, TFIIH complex, ERCC1/XPF and
XPG) are recruited to the DNA damage recognition complexes in both TCR and
GGR to remove the damage in a common pathway. Over-expression of XPA and
ERCC1 mRNA has been associated with cisplatin resistance in OC (Dabholkar,
et aI., 1994). In the current study, cisplatin induced XPA (Figure 178, panel c)
that was suppressed by hyperthermia co-treatment (Figure 17 panel c).
Suppression of XPA might decrease repair of cisplatin-DNA damage. ERCC1
was modestly induced «1.5 fold) by sodium arsenite co-treatment with cisplatin at
37°C (CPA37) (Figure 178, panel d).
In addition to the NER pathway, the mismatch repair (MMR) system has
been implicated in cisplatin resistance (Fink, et aI., 1997). In an effort to repair
platinum-DNA damage by the MMR system, a futile MMR occurs leading to cell
death (Martin, et aI., 2008; Topping, et aI., 2009). Ovarian cancer cells overexpressing MMR proteins are sensitive to cisplatin (Ding, et aI., 2009; Pani, et aI.,
2007; Topping, et aI., 2009). I report for the first time that tumors treated with
cisplatin at 37°C (CP37) significantly suppressed MSH2 consistent with
resistance. The observed suppression of MSH2 by cisplatin was reversed in
tumors co-treated with sodium arsenite at 37 or 43°C (CPAl37 and CPAl43
respectively). Thus, sodium arsenite at 37 or 43°C has the potential to sensitize
tumors to cisplatin by maintaining functional MMR.
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Cisplatin causes serious and dose-limiting side effects including kidney
damage, peripheral sensory neuropathy, cardiovascular toxicity,
myelosuppression and anemia which occur as a result of diffusion of
chemotherapy from the peritoneal to systemic compartment. In addition, arsenic
also causes adverse side effects including cardiovascular toxicity, kidney
damage, myelosuppression and anemia, liver damage and peripheral sensory
neuropathy. Understanding the biodistribution of these drugs during peritoneal
perfusion of chemotherapy is important in order to predict the occurrence of
these adverse side effects and determine the risk:benefit balance in performing
intraperitoneal perfusion with cisplatin and arsenic. For this reason, I determined
platinum and arsenic accumulation in the brain, heart, liver, kidney and spleen
during (0 h) and 24 h after perfusion. I observed that platinum and arsenic
accumulated to similar extent in these tissues regardless of the treatment
condition. The greatest accumulation of platinum was observed in the kidney, the
site of platinum elimination. Likewise, greatest level of arsenic was observed in
the liver, the organ for arsenic metabolism and detoxification. Even though I did
not observe any toxicity with the short-term survival study, accumulation of
arsenic and platinum in assayed organs suggests that potential adverse side
effects such as encephalopathy, cardiotoxicity, liver damage, renal damage and
myelosuppression/anemia respectively may occur during long-term survival
studies.
In summary, treatment of tumors with cisplatin plus sodium arsenite or
combined cisplatin, sodium arsenite and hyperthermia is most likely to enhance
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cisplatin efficacy because sodium arsenite ± hyperthermia impairs NER by
inhibiting induction of p53 and XPC and activates MMR by maintaining high
levels of MSH2 and enhances platinum accumulation in tumors. Sodium arsenite
and hyperthermia might not produce added systemic toxicity to cisplatin
chemotherapy; on the contrary, the combined treatment might help in the
clearance of platinum from tissues. Long-term survival studies are required to
determine the efficacy of this new combination chemotherapy. The murine
HIPEC model may serve as a useful tool to study in vivo mechanisms of platinum
resistance and explore ways to sensitize tumors to platinum chemotherapy.
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CHAPTER 4

CISPLATIN, SODIUM ARSENITE AND HYPERTHERMIA INDUCE PSEUDOG1 ASSOCIATED APOPTOTIC CELL DEATH IN OC CELLS
INTRODUCTION
Cisplatin and its analogues are widely used to treat ovarian, testicular,
head and neck, bladder, gastric and lung cancer (Vasey, et aI., 1999; Winter and
Albers, 2011; Pan, etal., 2009; Mitsui, etal., 2011; Norman, etal., 2010;
81ackhall and Faivre-Finn, 2011). The cytotoxicity of cisplatin is mediated through
cisplatin-DNA damage formation. Cisplatin primarily forms 1 ,2-intrastrand cross
links between adjacent purines and to a lesser extent 1,3-intrastrand cross links,
monoadducts and interstrand crosslinks (8asu and Krishnamurthy, 2010). In
addition to DNA damage, cisplatin can also form covalent bonds with biologically
important macromolecules such as protein and RNA.
Inherent and/or acquired resistance to cisplatin limits clinical success
(Armstrong, 2002a). One approach to mitigate cisplatin resistance is the use of
combination chemotherapy. My dissertation research project focuses on
investigating the cytotoxic effects and mechanisms of action of a new
combination of cisplatin, sodium arsenite and hyperthermia. I previously showed
that combined sodium arsenite and hyperthermia sensitize wild-type p53
expressing OC cells to cisplatin (Figure 3, Chapter 2). Mechanistically, sodium
arsenite and hyperthermia attenuated DNA repair protein XPC in vitro and in vivo
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(Figure 6 and Figure 17) and enhanced cellular and DNA accumulation of
cisplatin (Figures 1OB and 16).

90

In response to platinum-DNA damage, p53 is stabilized and activated by
upstream kinases. Activated p53 activates cell cycle checkpoints, DNA repair
and apoptosis (Abraham, 2001; Horvath, et aI., 2007). P53 regulates cell cycle
checkpoints by inducing transcription of cyclin dependent kinase inhibitor
CDKN1A, GADD45 and 14-3-30 (8asu and Krishnamurthy, 2010; Taylor and
Stark, 2001). CDKN1A blocks cell cycle progression by binding and inactivating
cyclin/CDK complexes which are required for pRb phosphorylation in order to
release E2F for cell cycle progression through G1. Cisplatin is known to cause
G2 arrest (Horvath, et aI., 2007). CDKN1A blocks G2 to M transition by binding
and inactivating CDK1/cyciin 8 complex (Taylor and Stark, 2001).
Sodium arsenite causes mitotic arrest and mitotic arrest associated
apoptosis (mitotic catastrophe) (McNeely, et aI., 2008b; McNeely, et aI., 2008a).
P53 has been implicated in sodium arsenite induced mitotic arrest. Presence of
functional p53 promotes mitotic exit (McNeely, et aI., 2006), whereas, cells with
non-functional p53 are more susceptible to sodium arsenite-induced mitotic
arrest (Taylor, et aI., 2006). In addition, a functional spindle checkpoint is
required for arsenite-induced mitotic arrest and apoptosis (McNeely, et aI.,
2008b; Wu, et aI., 2008). Similar to sodium arsenite, hyperthermia has been
reported to induce mitotic catastrophe in cancer cells (Grzanka, et aI., 2008;
Michalakis, et aI., 2005; Nakahata, et aI., 2002). Therefore, I hypothesized that
combined sodium arsenite and hyperthermia will enhance mitotic catastrophe in
cisplatin treated DC cells.
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The purpose of the studies in this chapter is to determine if a new
combination of sodium arsenite and hyperthermia alters cisplatin-induced G2 cell
cycle arrest and causes mitotic arrest and mitotic arrest associated apoptosis
(mitotic catastrophe) in wild-type p53 expressing OC cells treated with cisplatin. I
show that cisplatin, sodium arsenite and hyperthermia fails to activate spindle
assembly checkpoint protein BUBR1 and causes cells to exit mitosis without
dividing. Cells accumulate in pseudo-G1 with 2C DNA content and subsequently
underwent apoptotic cell death.
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HYPOTHESIS
Sodium arsenite and hyperthermia sensitize DC cells to cisplatin by
causing mitotic arrest associated apoptotic cell death.
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MATERIALS AND METHODS
Western blot analyses
Cells were treated and protein Iysates prepared and resolved by SDSpolyacrylamide gel electrophoresis as previously described in Materials and
Methods section in Chapter 2. Membranes were probed with mouse monoclonal
antibodies for /1-actin (Sigma, # A 5441, 1: 10,000 dilution), GAPDH (Ambion, #
AM4300, 1:10,000 dilution), cyclin A (Cell Signaling, # 4656,1:1000 dilution),
cyclin B (BD Biosciences PharMingen, # 55477, 1:1000 dilution), histone H3
Ser10 phosphorylation (Cell Signaling, # 9706S, 1: 1000 dilution) and cyclin E
(BD Biosciences PharMingen # 51-1459GR, 1:1000 dilution) or rabbit polyclonal
antibodies for CDKN1A (H-164, Santa Cruz, # SC 756, 1:1000 dilution), CDK1
(Upstate Cell Signaling Solutions, # 06-141, 1:1000 dilution) and pRbSer807/811
phosphorylation (cell signaling, # 9308, 1: 1000 dilution). Secondary antibodies
(rabbit anti-mouse IgG, # 81-6120 or goat anti-rabbit, # 81-6120) conjugated to
horseradish peroxidase (Zymed laboratories, Inc. South San Francisco, CA)
were bound to primary antibodies and protein bands detected using enhanced
chemiluminescence (ECl) substrate (Pierce, Rockford, Il). Bands for BUBR1,
cyclin E, CDK1 Y15P, histone H3 Ser10P and GAPDH were detected using
enhanced chemiluminescence (ECl) plus western blotting detection system (GE
Healthcare, RPN2132) and bands were developed using Molecular Dynamics
Storm 860 (GE Healthcare BioSciences) in blue fluorescence mode. /1-actin and
GAPDH served as the loading control.
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Flow cytometry analyses
Cells (1 X 106 ) were cultured in 10 cm dishes overnight and treated with
IC50 cisplatin (A2780

=4 ~M and A2780/CP70 =40 ~M) ± 20 IJM sodium

arsenite at 37 or 39 Cc for 1 h. Cells were washed twice with PBS and refed with
fresh media and incubated at 37 cC. Whole cells were trypsinized and collected
at 0 and 36 h, washed twice with PBS and fixed in 70% ethanol overnight at 4 cC.
Cells in 0.5 mL PBS were incubated at 37 cc with RNase A (100 U/mL) for 30
min. After adding propidium iodide (5 IJg/mL), cells were incubated at room
temperature for 30 min protected from light. Propidium iodide fluorescence (DNA
content) was determined by flow cytometry using FACScalibur (BD Biosciences,
San Jose, CA). A minimum of 20,000 cells/sample were analyzed. Data were
collected and analyzed using FLOWJO software (FLOWJO, Ashland, OR).
Mitotic Index determination
Cells (5 X 105/6 cm dish) were treated with IC50 cisplatin (A2780 = 4 ~M
and A2780/CP70 = 40 ~M) ± 20 IJM sodium arsenite at 37 or 39 Cc for 1 h. The
cell monolayers were washed twice with PBS and incubated in drug-free media
for 36 h. Cells were washed twice with cold PBS, trypsinized using 1x trypsin
and collected by centrifugation at 500 xg for 5 min. Cells were resuspended in
150

~L

serum free media and 2.5 mL of 0.4% KCI was added. The cell

suspension was incubated for 10 min at 37 cC. Methanol:acetic acid (3: 1 v/v)
fixation solution was added to 2% v/v and cells collected by centrifugation at 500
xg for 5 min. Cells were resuspended in 2.5 mL fixation solution and fixed at
room temperature for 20 min. Samples were centrifuged at 500 xg for 5 min and
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pellets resuspended in 0.5 mL fixation solution and chilled on ice for a minimum
of 20 min. Aliquots of the suspensions were dropped onto slides (2 slides per
sample), air dried for about 1 min and stained with Wright Giemsa solution
(States, et aI., 2002). Slides were examined under a microscope and a minimum
of 200 nuclei were counted on each slide for determination of mitotic index and
mitotic catastrophe index. Chromosomal spreads with sharp features were
scored as mitotic nuclei (Taylor, et aI., 2006)
Annexin V-FITe apoptosis assay
Cells (5 X 105/6 cm dish) were treated with IC50 cisplatin (A2780
and A2780/CP70

=4 ~M

=40 ~M) ± 20 IJM sodium arsenite at 37 or 39°C for 1 h. The

cell monolayers were washed twice with PBS and incubated in drug-free media
for 36 h. Cells were trypsinized using 1x trypsin and collected by centrifugation at
500 xg for 5 min. Cells were resuspended in 500
of annexin V-FITC and 5

~L

~L

of propidium iodide (50

of 1X binding buffer and 5
~g/mL).

~L

Samples were

incubated at room temperature in the dark for 5 min. Annexin V-FITC binding
was analyzed by flow cytometry (excitation

=488 nm; emission =530 nm) using

FACScalibur (BO Biosciences, San Jose, CA). Minimum of 20,000 cells/sample
were analyzed. Annexin V assay was performed following manufacturers'
instructions (Cat #: K101-25, BioVision Research Products, Mountain View, CA).
Statistical analysis
Results were expressed as the mean ± SO of three independent
experiments. Statistical analyses were performed using Microsoft Excel built in
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formulas for one-way analysis of variance and student's t-test with significance
level as p < 0.05, n

=3.
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RESULTS
Flow cytometry determination of cell cycle arrest
Cisplatin is a DNA damaging agent. Cellular response to DNA damage
involves cell cycle arrest to allow time to repair damaged DNA (8asu and
Krishnamurthy, 2010). Cisplatin is known to cause G2 arrest (Cepeda, et aI.,
2007). The goal of this experiment was to determine if sodium arsenite and
hyperthermia alter the accumulation of cells in the G2/M compartment of the cell
cycle following cisplatin treatment. Data suggest that both A2780 and
A2780/CP70 cells accumulated in the G2/M compartment 36 h after cisplatin
IC50 exposure (Figure 20). A2780/CP70 cells accumulated in the G2/M
compartment to a greater extent than A2780 cells. Accumulation was not altered
by sodium arsenite and/or hyperthermia co-treatment with cisplatin.
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Figure 20
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Figure 20. Cell cycle analyses by flow cytometry. A. Representative
histogram of untreated cells (left panel) showing no cell cycle arrest and cisplatin
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treated cells (right panel) accumulating in the G2/M compartment. B. Plot of
percentage of cells in each phase of the cell cycle. A2780 and A2780/CP70 cells
were treated with their IC50 cisplatin (CP) (A2780, 4 IJM; CP70, 40 IJM), CP plus
20 IJM sodium arsenite at 37 or 39°C for 1 h. Cells were harvested at 0 and 36 h
after treatment. DNA content was analyzed by flow cytometry after propidium
iodide staining. Data are the means ± SO of samples from 2 independent
experiments. Each experiment was performed in duplicate dishes. Statistically
analysis was performed using one way ANOVA and student t test. P<0.05,
compared to G2/M partners.
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Sodium arsenite and hyperthermia effect on G2 and M cell cycle regulatory
proteins
Flow cytometry determination of DNA content using propidium iodide does
not distinguish between G2 and M cells because these cells both have 2C DNA
content. In order to determine if cells are in the G2 or M phase of the cell cycle at
36 h after treatment, the expression of cyclin A and cyclin Band cyclin
dependent kinase CDK1 were determined. Furthermore, I determined if sodium
arsenite and hyperthermia alter the expression of cyclin A, cyclin Band CDK1 in
response to cisplatin treatment. G2 to M progression requires degradation of
cyclin A and accumulation of cyclin B (Malumbres and Barbacid, 2009). Data in
Figure 21 indicate that cisplatin treatment at 37°C stabilized CDK1, cyclin A and
cyclin B (Figure 21, panel a), suggesting G2 arrest. Adding hyperthermia to
cisplatin decreased the levels of both cyclin A and cyclin B in A2780 cells
suggesting G1 arrest, whereas; in A2780/CP70 cells cyclin A and cyclin B were
stabilized suggesting G2 arrest (Figure 21, panel b). Co-treatment with cisplatin
and sodium arsenite decreased both cyclin A and cyclin B in A2780 cells
suggesting G1 arrest; while in A2780/CP70 cells, cyclin A was undetected, while
cyclin B was stabilized, suggesting mitotic arrest (Figure 21, panel c). Combined
cisplatin, sodium arsenite and hyperthermia stabilized cyclin Band CDK1 but
attenuated the expression of cyclin A in both cell lines at 36 h after treatment
(Figure 21, panel d), suggesting mitotic arrest. These data suggest that
combined sodium arsenite and hyperthermia induced mitotic arrest in cisplatin
treated cells.
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Figure 21
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Figure 21. Western blot analyses of G2/M cell cycle regulatory proteins.
Cells were treated with their respective IC50 cisplatin (CP) (A2780, 4 IJM ; CP70,
40 IJM), or CP plus 20 IJM sodium arsenite (CPA) at 37 or 39 aC (hyperthermia)
for 1 h, then washed with PBS and refed with fresh media and incubated at 37

aC . Cells Iysates were prepared at 0, 24 and 36 h. ~-actin is the loading control.
Blots shown are representative of 2 independent experiments.
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Sodium arsenite and hyperthermia do not enhance mitotic index in
cisplatin treated cells and also failed to induce histone H3 Ser10
phosphorylation
Data in Figure 21 suggest that combining sodium arsenite and
hyperthermia with cisplatin is causing treated cells to arrest in mitosis. In order to
confirm if indeed these cells are in mitosis, I determined mitotic index as
described in Materials and Methods section. Adding sodium arsenite and/or
hyperthermia to cisplatin did not increase the mitotic index in both A2780 and
A2780/CP70 cells (Figure 22). The observed low mitotic index suggested that
sodium arsenite and hyperthermia do not induce mitotic arrest in cisplatin treated
cells.
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Figure 22
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Figure 22. Mitotic index determination. A. Representative picture of (a) mitotic
spread and (b) interphase nuclei. B. Plot of means of percentage of mitotic index
for duplicate slides . Cells were treated with their respective IC50 cisplatin (CP)
(A2780, 4

~M ;

CP70 , 40

~M) ,

or CP plus 20

~M

sodium arsenite (CPA) at 37 or

39°C (hyperthermia) for 1 h. Treated cells were washed with PBS and refed
fresh media and incubated at 37°C for 36 h. Mitotic index was determined at 36 .
h after treatment. Data are single biological experiments performed in duplicate
dishes.
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Mitotic index data in Figure 22 indicate that less than 3% of cells were
undergoing mitotic arrest. In order to confirm this finding, I performed western
blot analysis of histone H3 phosphorylated on Serine 10 (H3Ser10P), a mitotic
marker, (Figure 23). H3Ser10P was undetected in both A2780 and A2780/CP70
cells treated with cisplatin ± sodium arsenite at 37 or 39 aC. These data
confirmed that a large fraction of cells were not in mitosis.

105

Figure 23
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Figure 23 .. Western blot analysis of protein marker of mitotic arrest.
Western blot analysis of H3Ser1 OP. Cells were treated with their respective IC50
cisplatin (CP) (A2780, 4

~M ;

A2780/CP70 , 40 ~M), or CP plus 20 ~M sodium

arsenite (CPA) at 37 or 39°C (hyperthermia) for 1 h. Treated cells were washed
with PBS and refed fresh media and incubated at 37°C. Protein Iysates were
prepared at 36 h for western blot analysis. Data are representative from duplicate
biological experiments . A375 cells were treated with 5 11M sodium arsenite for 24
h served as positive control for mitotic cells. r.,-actin served as loading control.

106

Cisplatin, sodium arsenite and hyperthermia prevent BUBR1
phosphorylation
A functional spindle assemble checkpoint is required for mitotic arrest. The
mitotic spindle checkpoint complex consists of MAD3/BUBR1, BUB3 and MAD2
(Tan, et aI., 2005). The mitotic spindle checkpoint induces mitotic arrest by
inhibiting anaphase onset by associating with CDC20, a subunit of the anaphase
promoting complex (APC). Therefore, I determined if A2780 and A2780/CP70
cells have functional spindle checkpoint by determining the phosphorylation of
BUBR 1 following 100 nM taxol treatment for 16 h. I observed that taxol treatment
induced BUBR1 phosphorylation in A2780 and A2780/CP70 cells (Figure 24),
indicating that these cells have functional spindle assembly check point.
However, cisplatin or its co-treatment with sodium arsenite and hyperthermia
failed to induce BUBR1 phosphorylation (Figure 24); suggesting that mitotic
spindle checkpoint is disrupted.
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Figure 24

Cisplatin (f.lM)

-

A2780
A2780/CP70
++++-++++

NaAs02 (f.lM)

-

-+

Hyperthermia (39 'C)

-

--++---++

-+

--+-+

Figure 24. Western blot analysis of mitotic spindle assembly checkpoint
protein. Western blot analysis of BUBR 1 and phosphorylated BUBR 1 in control
Iysates treated with 100 nM taxol 16 h. Cells were treated with their respective
IC50 cisplatin (CP) (A2780 , 4 IJM; A2780/CP70 , 40 IJM), or CP plus 20 IJM
sodium arsenite (CPA) at 37 or 39

Cc (hyperthermia) for 1 h. Treated cells were

washed with PBS and refed fresh media and incubated at 37 cC. Protein Iysates
were prepared at 36 h after treatment for western blot analysis. Data are
representative of triplicate biological experiments. GAPDH served as loading
control.
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Cispiatin, sodium arsenite and hyperthermia induced pseudo-G1 arrest in

OC cells
Data in Figure 24 suggest that cisplatin ± sodium arsenite at 37 or 39°C
are disrupting the mitotic spindle assembly checkpoint in A2780 and
A2780/CP70 cells. Absence of mitotic spindle checkpoint activation allows cells
with damaged DNA to exit mitosis and progress through the cell cycle to G1
without dividing and end up with double DNA content (2C) (Lanni and Jacks,
1998). Therefore I determined if the cells were undergoing pseudo-G1 arrest by
determining the expression of CDKN1A, pRbSer807/811 P and cyclin E using
western blot analysis. Data in Figure 25 suggest that cisplatin stabilized
CDKN1A over time and decreased pRbSer807/811 Pat 36 h after treatment
(Figure 25A panel a). Adding sodium arsenite ± hyperthermia (Figure 25A,
panels c, band d respectively) caused stronger CDKN1A induction and
decreased levels of pRbSer807/811P compared with cisplatin alone at 37°C
(Figure 25, panels b, c and d). These data confirmed that G1 arrest is taking
place at 36 h after treatment. I also observed that cyclin E was stabilized in both
A2780 and A2780/CP70 cells when compared to mitotic positive A2780 and
A2780/CP70 cells that did not express cyclin E (Figure 258). These data suggest
that cisplatin alone or combined with sodium arsenite and hyperthermia is
inducing pseudo-G1 arrest in A2780 and A2780/CP70 cells.
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Figure 25
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Figure 25. Western blot analysis of protein markers of G1 arrest. A. Western
blot analysis of CDKN1A and pRbSer807/811 P. Panel (a) is CP 37°C, (b) is CP
39°C , (c) is CPA 37 °C and (d) is CPA39 °C. B. Western blot analysis of cyclin E.
Cells were treated with their respective IC50 cisplatin (CP ; A2780 , 4 !-1M ; CP70,
40 !-1M) , or CP plus 20 !-1M sodium arsenite (CPA) at 37 or 39°C (hyperthermia)
for 1 h. Cells were washed with PBS and refed with fresh media and incubated at
37°C . Cell Iysates were prepared at 0, 6, 12, 24 , and 36 h. ~-actin and GAPDH
are loading controls. A2780 and A2780/CP70 cells were treated with 100 nM
Taxol for 16 h and served as negative control for cyclin E.
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Cispiatin, sodium arsenite and hyperthermia induce apoptotic cell death in
pseudo-G1 arresting cells
Data in Figure 25 suggest that cisplatin, sodium arsenite and hyperthermia
are causing pseudo-G1 arrest in DC cells. I performed FITC Annexin V
propidium iodide assay to determine if pseudo-G1 cells were undergoing
apoptosis. Data suggest that cisplatin alone or combined with sodium arsenite
and/or hyperthermia significantly induced apoptotic cell death (-15%) at 36 h
after treatment (Figure 26).
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Figure 26
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Figure 26. Apoptotic cell death determination using File Annexin V
propidium iodide assay. Cells were treated with their respective IC50 cisplatin
(CP) (A2780 , 4 !-1M ; CP70, 40 !-1M) , or CP plus 20 !-1M sodium arsenite (CPA) at
37 or 39°C (hyperthermia) for 1 h. Treated cells were washed with PBS and
refed fresh media and incubated at 37°C for 36 h. Cell death was determined at
36 h after treatment. Data are means ± SO of triplicate biological experiments.
Statistically analysis was performed using one way ANOVA and Turkey test.
P<0 .05 , a

=compared to untreated (UT) A2780 cells, b =compared to untreated

A2780/CP70 cells.

112

DISCUSSION
This study was aimed at determining if a new combination of sodium
arsenite and hyperthermia altered cisplatin-induced G2 cell cycle arrest and
induced mitotic arrest and mitotic arrest associated-apoptosis (mitotic
catastrophe) in OC cells treated with cisplatin. I used a well characterized and
widely used human OC cell model for cisplatin-sensitive (A2780) and its cisplatinresistant subline (A2780/CP70) for this study. I showed that sodium arsenite and
hyperthermia does not alter cisplatin-induced accumulation of cells in the G2/M
compartment when analyzed by flow cytometry for DNA content. However,
cisplatin alone or combined with sodium arsenite and/or hyperthermia failed to
activate the mitotic spindle checkpoint which allowed cells to exit mitosis and
enter pseudo G1 with 2C DNA content. These cells then underwent apoptotic cell
death.
Flow cytometry determination of DNA content using propidium iodide does
not distinguish between G2 and M cells because they both have 2C DNA
content. Therefore I used western blot analysis to determine the expression of
G2/M regulatory proteins cyclin A and cyclin B. Cyclin A is usually degraded
before cells enter mitosis, whereas cyclin B is stabilized during mitosis
(Malumbres and Barbacid, 2009). Stabilization of cyclin A and cyclin B by
cisplatin (CP 37°C) in both A2780 and A2780/CP70 cells suggest G2 arrest
(Figure 21, panel a), consistent with previous findings (Cepeda, et aI., 2007).
Decreased expression of cyclin A and cyclin B by hyperthermia co-treatment with
cisplatin (CP 39°C) in A2780 cells is consistent with G1 arrest (Figure 21, panel
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b). Decreased expression of cyclin A and cyclin B by sodium arsenite cotreatment with cisplatin (CPA 37°C) in A2780 cells is consistent with G1 arrest
(Figure 21, panel c). Sodium arsenite co-treatment with cisplatin (CPA 37°C)
decreased expression of cyclin A and stabilized cyclin B in A2780/CP70 cells
(Figure 21, panel c), consistent with mitotic arrest. Sodium arsenite plus
hyperthermia co-treatment with cisplatin (CPA 39°C) attenuated expression of
cyclin A and it stabilized cyclin B in both cell lines (Figure 21, panel d), consistent
with mitotic arrest. However, mitotic arrest in A2780/CP70 cells treated with CPA
37°C or in A2780 and A2780/CP70 cells treated with CPA 39°C was not
supported by mitotic index or histone H3Ser10P data (Figures 22 and 23
respectively). Sodium arsenite and hyperthermia did not increase mitotic index in
cisplatin treated cells and undetected levels of histone H3 phosphorylation
(H3Ser10P) clearly indicated that arsenite co-treated cells are not arresting in
mitosis.
Mitosis is the phase of the cell cycle where cells divide to produce two
genetically identical cells from one cell. In order to ensure proper division, the
mitotic spindle checkpoint must ensure that all chromosomes are attached to the
kinetochores by microtubules and that proper tension is exerted on the
kinetochores before mitotic exit (Zhou, et aI., 2002; Tan, et aI., 2005). Cells with
defective spindle checkpoint will proceed through the cell cycle with aberrant
chromosomes. The mitotic spindle checkpoint complex consists of
MAD3/BUBR1, BUB3 and MAD2 (Tan, et aI., 2005). The mitotic spindle
checkpoint inhibits anaphase onset by associating with CDC20, a subunit of the
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anaphase promoting complex (APC). APC is an E3-ubiqitin ligase that mediates
degradation of securin and cyclin B. Degradation of securin and cyclin B is
required for anaphase onset and subsequent mitotic exit. Treatment of A2780
and A2780/CP70 cells with a mitotic arrest inducing drug taxol caused
phosphorylation of BUBR1 in these cells (Figure 24). Phosphorylation of BUBR1
suggests that these cells have functional spindle assembly checkpoint. However,
cisplatin ± sodium arsenite treatment at 37 or 39°C failed to activate
BUBR1 phosphorylation in OC cells (Figure 24). Disruption of mitotic spindle
checkpoint may allow cells to exit mitosis without undergoing cytokinesis.
In response to DNA damage, p53 is stabilized and activated and it
transcriptionally activates CDKN1A expression. Induced CDKN1A binds to and
inhibits CDK2/cyciin E complex, preventing the phosphorylation of pRb, thus
blocking cells in G1. I observed strong induction of CDKN1A and suppression of
pRb Ser807/811 P (Figure 25) at 36 h after treatment suggested that G1 arrest is
taking place. Accumulation of cells in G1 was supported by the stabilization of
cyclin E (Figure 25B). The data clearly suggest that the cells accumulating in the

G2/M compartment underwent endoreduplication and exited mitosis without
cytokinesis and subsequently accumulated in G1 with 2C DNA content. The
phenomenon of cells with disrupted spindle checkpoint undergoing
endoreduplication and exiting mitosis without cytokinesis was previously
observed by Lanni and Jacks (Lanni and Jacks, 1998). Lanni and Jacks showed
that when mouse embryo fibroblasts were treated with spindle inhibitor
nocodazole, these cells accumulated transiently in mitosis and progressed into
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G1 with 4N DNA content. These cells were classified as pseudo-G1 cells
because they showed upregulated cyclin E and hypophorylated pRb, but had 4N
DNA content similar to G2/M cells. Cells with disrupted spindle checkpoint are
expected to be resistant to sodium arsenite induced mitotic arrest and apoptosis
(McNeely, et aI., 2008b; Wu, et aI., 2008). However, these pseudo-G1 cells
underwent apoptotic cell death in response to cisplatin treatment and cotreatment with sodium arsenite andlor hyperthermia resulted in greater
percentage of dead cells (Figure 26).
In summary, I have shown for the first time that cisplatin ± sodium arsenite
at 37 or 39°C disrupts the mitotic spindle checkpoint and causes cells to exit
mitosis without dividing and subsequently accumulating in G1. These pseudo-G1
cells with 2C DNA content stabilized cyclin E and induced CDKN1A and
decreased pRb Ser807/811 P. In addition these pseudo-G1 cells underwent
apoptotic cell death. These data suggest potential new mechanisms by which
cisplatin or its combination with sodium arsenite and hyperthermia induce cell
death in wild-type p53 expressing DC cells.
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CHAPTER 5
HSP90 INHIBITOR 17-DMAG ROBUSTLY ENHANCES THE
CYTOTOXICITY OF COMBINED CISPLATIN, SODIUM ARSENITE AND
HYPERTHERMIA AGAINST OC
INTRODUCTION
Ovarian cancer is the most common cause of gynecologic cancer death in
women in the United States (Jemal, et aI., 2010). Cisplatin or carboplatin with
taxane is used in the frontline treatment of OC following cytoreductive surgery
(McGuire, et aI., 1996). Inherent and/or acquired resistance decreases
effectiveness of platinum-based chemotherapy, and only about 20% of women
survive for 5 years once diagnosed with OC (Armstrong, 2002; Rubin, et aI.,
1999). Thus, finding a new effective treatment regimen to mitigate cisplatin
resistance is highly needed.
Cisplatin exerts its cytotoxic effect by causing DNA damage. In addition to
its effect on DNA, cisplatin binds to non-DNA targets such as glutathione,
metallothionein, protein and RNA (Cepeda, et aI., 2007). Cisplatin also binds to
the C-terminus of HSP90 and interferes with ATP binding (Donnelly and Blagg,
2008; Landriscina, et aI., 2010). Binding of cisplatin to non-DNA targets may give
rise to cytotoxic oxidative and electrophile stress (Jacobs and Marnett, 2010).
Presence of cellular stress induces drug metabolizing enzymes and antioxidant
proteins such as hemoxygenase (HO-1), quinine oxidoreductase (NQ01) and
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nicotinamide adenine dinucleotide phosphate (NAD(P)H) via NRF2 binding to
antioxidant and electrophile response elements (Nerland, 2007). In addition, heat
shock factor 1 (HSF1) protects against oxidative and electrophile-induced toxicity
by inducing pro-survival heat shock genes such as HSP70, HSP11 0 and HSP40
that function to fold denatured proteins (Landriscina, et aI., 2010). These
defensive mechanisms additionally contribute to cisplatin resistance.
Combination chemotherapy has been implemented to enhance cisplatin
cytotoxicity. I previously showed that combined sodium arsenite and
hyperthermia sensitized wild-type p53 expressing OC cells to cisplatin (Figure 3,
Chapter 2) by suppressing XPC (Figure 6, Chapter 2) and enhancing cellular
(Figure 10B, Chapter 2) and DNA (Figure 12, Chapter 2) accumulation of
platinum. Cisplatin and sodium arsenite can generate oxidative and electrophile
stress and hyperthermia can generate oxidative and heat stress (Jacobs and
Marnett, 2010). Cellular response to stress involves induction of stress response
proteins to protect the cells from dying.
The goal of this study is to investigate if inhibiting the activity of the
molecular chaperone, HSP90 will sensitize both p53 (+) and p53 (-) OC cells to
cisplatin. Cisplatin, sodium arsenite and hyperthermia induced HSP60 and
HSP70 and stabilized HSP90 in A2780 and A2780/CP70 cells. PARP-1 cleavage
was observed in these cells, suggesting that apoptosis is occurring. Inhibition of
HSP90 activity using 17-(Dimethylaminoethyamino )-17 -demethoxygeldanamycin
(17-DMAG) remarkably potentiated the cytotoxicity of combined cisplatin, sodium
arsenite and hyperthermia (CPA 39°C) against OC cells in a p53-independent
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manner. Enhanced cellular accumulation of cisplatin was observed with 17DMAG co-treatment with CPA 39°C. These data suggest that 17-DMAG has the
potential to reverse cisplatin resistance when co-treated with CPA 39°C.
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HYPOTHESIS
Cisplatin, sodium arsenite and hyperthermia induce cellular stress. Inhibition of
HSP90, a key modulator of stress response will potentiate the cytotoxicity of
combined cisplatin, sodium arsenite and hyperthermia against ac.
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MATERIALS AND METHODS

Chemicals
Stock and working solutions of 17-DMAG (17-(Dimethylaminoethyamino)17-demethoxygeldanamycin) (InvivoGen, San Diego, California, # NSC 707545)
were prepared in sterile water and stored at -20°C protected from light.

Cell Viability assay
The growth inhibitory effects of cisplatin, sodium arsenite, hyperthermia
and 17-DMAG were evaluated using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5diphenyltetrazolium bromide) cell viability assay (Mosmann, 1983) as described
in the Materials and Methods section of Chapter 2 with some modifications.
Briefly, 2500 cells/well were seeded overnight in 96-well plates. Next day, cells
were treated with cisplatin ± 20 IJM sodium arsenite and/or 100 nM of 17-DMAG
at 37 or 39°C for 1 h. After treatment, cells were washed twice with PBS and
refed with drug-free medium and incubated at 37°C for 5 days prior to assay.
Blank was cells treated with 0.1 mg/mL hygromycin B. MTT assay was measured
at 570 nm. The absorbance values corresponded to the number of viable cells.
Cell viability was calculated as follows and plotted against concentration of
cisplatin.
01
/0

II· b·l·t _ 100 x (mean of triplicate treated samples - Blank)
ce via I I Y . .
(Mean of triplicate untreated samples - Blank)

Data were expressed as means ± SEM of at least four independent experiments.
Each experiment was done with triplicate wells for each treatment condition.
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Western blot analyses
Total cellular Iysates were prepared at 2 and 24 h after treatment. Cell
Iysates were prepared and proteins were separated on 10 % SOSpolyacrylamide gel electrophoresis as previously described in Materials and
Methods section of Chapter 2. Membranes were probed with mouse monoclonal
antibodies for HSP90 (F-8, Santa Cruz Biotechnology, Santa Cruz, CA, dilution
1: 1000), ~-actin (Sigma, # A 5441, dilution 1: 10,000), or rabbit polyclonal
antibodies for PARP-1, HSP70 (Cell Signaling Technology, dilution 1: 1000) and
HSP60 (Chemicon International, Millipore, Temecula, CA, 1:1000). Secondary
antibodies (rabbit anti-mouse IgG, # 81-6120 or goat anti-rabbit, # 81-6120,
dilution 1:2500) conjugated to horseradish peroxidase (Zymed laboratories, Inc.
South San Francisco, CA) were bound to primary antibodies and protein bands
detected using enhanced chemiluminescence (ECl) substrate (Pierce, Rockford,
Il) followed by exposure to Kodak XAR x-ray film. ~-actin was used as the
loading control.

Platinum accumulation studies
5

Cells (5 X 10 16 cm dish) were treated with 40 IJM cisplatin ± 20 IJM
sodium arsenite with or without 100 nM of 17-OMAG at 37 or 39°C for 1 h.
Samples were prepared and analyzed using ICP-MS as previously described in
Materials and Methods section in Chapter 2.

Statistical analysis
Results were expressed as the mean ± SO of three independent
experiments. Statistical analyses were performed using Microsoft Excel built in
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formulas for one-way analysis of variance and student's t-test with significance
level as p < 0.05, n = 3.
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RESULTS
Cisplatin, sodium arsenite and hyperthermia induced stress response
proteins in DC cells
Treatment of cells with cisplatin or sodium arsenite can generate reactive
oxygen species and electrophiles that may cause oxidative DNA, lipid, RNA and
protein damage (Sahin, et aI., 2010; Davison, et aI., 2002). In addition,
hyperthermia may generate heat stress and denature important cellular proteins
(Hildebrandt, et aI., 2002). Thus, combined cisplatin, sodium arsenite and
hyperthermia may enhance cytotoxic cellular stress. Following cellular stress,
heat shock proteins are induced to fold denatured proteins and protect against
stress-induced cell death. This experiment was aimed at investigating if cisplatin,
sodium arsenite and hyperthermia induce stress response proteins in OC cells in
response to cellular stress. Cells were treated as described in Materials and
Methods Section. HSP90 was unchanged for all treatment conditions. HSP60
and HSP70 were induced at 2 and 24 h after treatment (Figure 27). Robust
induction of HSP70 occurred at 24 h after treatment for all treatment conditions
and in both cell lines. These data suggest that cisplatin, sodium arsenite and
hyperthermia both individually and in combination induce cellular stress.
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Figure 27
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Figure 27. Western blot analysis of stress response proteins. A2780 and
A2780/CP70 cells were treated with their IC50 cisplatin (CP) (A2780 , 4 IJM;
CP70, 40 IJM), CP plus 20 IJM sodium arsenite (CPA) at 37 or 39 °C for 1 h. After
treatment, cells were washed with 1X PBS , incubated in fresh media at 37 cC .
Protein Iysates were collected at 2 and 24 h after treatment for western blot
analysis. Blots are representative of two independent experiments. Ponceau
stained picture serves as loading control.
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Cispiatin, sodium arsenite and hyperthermia induce apoptotic cell death in

OC cells
Data in Figure 27 indicate that cisplatin, sodium arsenite and hyperthermia
each induced stress response proteins HSP60 and HSP70 and did not change
HSP90 levels. I then determined if induction of stress response proteins is
associated with apoptotic cell death. Western blot analysis technique was used
to determine PARP-1 cleavage (Figure 28). Data indicate that PARP-1 is cleaved
24 h after treatment, suggesting that apoptotic cell death is occurring in these
cells at 24 h.
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Figure 28
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Figure 28. Western blot analysis of apoptotic proteins. A2780 and

A2780/CP70 cells were treated with their IC50 cisplatin (CP) (A2780 , 4
CP70 , 40

~M) ,

CP plus 20

~M

~M ;

sodium arsenite (CPA) at 37 or 39 °C for 1 h. After

treatment, cells were washed with 1X PBS , incubated in fresh media at 37°C .
Protein Iysates were collected at 2 and 24 h for western blot analysis . Blots are
representative of two independent experiments. Ponceau stained picture serves
as loading control.
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HSP90 inhibitor 17-DMAG potentiates cisplatin, sodium arsenite and
hyperthermia cytotoxicity against OC
Data in Figure 27 suggest that cisplatin, sodium arsenite and hyperthermia
are inducing cellular stress as evident by the induction of HSP60 and HSP70,
while HSP90 remained stable. Inhibiting the activity of heat shock proteins may
enhance the cytotoxicity of anticancer agents. HSP90 is a druggable target
because it is ubiquitously expressed in most cancer cells and it is integrally
involved in cell signaling, survival and proliferation (Taipale, et aI., 2010).
Furthermore, several HSP90 inhibitors have been extensively investigated as
anticancer agents and most are undergoing clinical trial (Messaoudi, et aI.,
2011). I determined if inhibition of HSP90 activity using 17-DMAG would
potentiate the cytotoxicity of cisplatin, sodium arsenite and hyperthermia against

oe.

I used a non-toxic dose of 17-DMAG (100 nM) (Figure 29) to treat the cells.
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Figure 29
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Figure 29. Cell viability effect of 17-DMAG on sodium arsenite

±

hyperthermia. Cells were treated with the indicated concentrations of 17-DMAG
± 20 IJM sodium arsenite at 37 or 39°C for 1 h. Cells were then washed twice
with PBS and refed with fresh media and incubated for 5 days at 37°C . Cell
viability MTT assay was performed 5 days after treatment. Data are expressed
as percentage of untreated control and plotted as means ± SD of at least four
independent experiments each performed with triplicate wells.
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Cell viability data suggest that 17-DMAG moderately enhanced the
sensitivity of wild-type p53 expressing A2780 and A2780/CP70 cells to cisplatin
(CP 37°C) or cisplatin plus arsenite (CPA 37°C) or cisplatin plus hyperthermia
(CP 39°C) (Figure 30A). Combined 17-DMAG and CPA 39°C greatly decreased
cell viability (Figure 308). P53-null SKOV-3 cells were not sensitized by 17DMAG when co-treated with CP 37°C or CPA 37 °c (Figure 30A, right panel).
However, 17-DMAG enhanced the cytotoxicity of CP 39°C and CPA 39 °C in
SKOV-3 cells (Figure 308, right panel). The enhancement of CPA 39°C was
greater than that of CP 39°C in SKOV-3 cells.
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Figure 30
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Figure 30. Cell viability as determined by MTT assay. A. Cells treated at 37

aC . B. Cells treated at 39 aC . Cells were treated with the indicated concentrations
of cisplatin with (CPA) or without (CP) ± 20

~M

sodium arsenite in the presence

(diamond symbol) or absence (circle symbol) of 100 nM of 17-DMAG at 37 or 39

aC for 1 h. Cells were then washed twice with PBS and refed with fresh media
and incubated for 5 days at 37 aC . Cell viability MTT assay was performed 5 days
after treatment. Data are expressed as percentage of untreated control and
plotted as means ± SEM of at least four independent experiments each
performed with triplicate wells. R-values for the best fitting polynomial curves
were all >0 .99.

131

HSP90 inhibitor 17-DMAG enhanced cellular accumulation of cisplatin
Data in Figure 308 suggest that 17-DMAG has the potential to reverse
cisplatin resistance when used in combination with cisplatin, sodium arsenite and
hyperthermia (CPA 39°C). In order to understand the mechanism involved in 17DMAG sensitization, I determined if 17-DMAG enhanced cellular accumulation of
cisplatin because decreased cellular accumulation of cisplatin is an important
mechanism of resistance (Parker, et aI., 1991). The results suggest that 17DMAG moderately increased platinum accumulation in A2780 and A2780/CP70
cells when co-treated with CPA 39°C (CPAD 39) (Figure 31, left and center
panels). Cisplatin accumulation in SKOV-3 cells was significantly higher (Figure
31, right panel).
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Figure 31
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Figure 31. ICP- MS analysis of cellular platinum accumulation. A2780 ,
A2780/CP70 and SKOV-3 cells were treated with 40 IJM cisplatin (CP37 and
CP39)) ± 20 IJM sodium arsenite (CPA37 and CPA39) and/or 100 nM of 17DMAG (CPAD39) at 37 or 39°C for 1h. Cells were harvested immediately after
treatment for total cellular platinum determination. Data are means ± SD from 3
independent experiments. N
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DISCUSSION
Cisplatin remains the drug of choice to treat OC. However, resistance
limits clinical success. Combination chemotherapy is at the forefront to improve
the efficacy of cisplatin and its analogues against OC. I showed in chapter 2 that
combined sodium arsenite and hyperthermia (CPA 39°C) sensitized wild-type
p53 expressing cells to cisplatin by mitigating mechanisms of cisplatin resistance
such as inhibiting DNA repair protein XPC and enhancing cellular platinum
accumulation and platinum bound to DNA. A potential mechanism of cytotoxicity
for combined cisplatin, sodium arsenite and hyperthermia (CPA 39°C) is
induction of oxidative, electrophile and heat stress (Davison, et aI., 2002;
Pandita, et aI., 2009; Hildebrandt, et aI., 2002; Jacobs and Marnett, 2010).
Cellular stress may denature key proteins required for signal transduction, cell
survival and proliferation by cancer cells. Heat shock proteins are intimately
involved in refolding these denatured proteins to the correct conformation,
thereby promoting survival (Landriscina, et aI., 2010). Therefore, inhibiting heat
shock protein function could sensitize cells to anticancer agents. The goal of this
study was to investigate if inhibition of HSP90 activity would further sensitize OC
cells to the combination of cisplatin, sodium arsenite and hyperthermia (CPA 39
°C) in a p53-independent manner. HSP90 inhibitor 17-DMAG at a non-toxic
concentration potentiated CPA 39°C cytotoxicity against OC cells. Presence of
cellular stress was evident by the induction of HSP60 and HSP70 in response to
cisplatin ± sodium arsenite treatment at 37 or 39°C. In addition, PARP-1
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cleavage occurred at 24 h after treatment, suggesting that apoptotic cell death is
occurring following cellular stress induction.
HSP90 is a highly conserved and ubiquitously expressed in most tissues
and cancer cells. It is a molecular chaperone and forms complexes with HSP70,
HSP40, CDC37/p50, p23, AHA1 and accessory molecules such as HSP
organizing protein (HOP), HSP-interacting protein (HIP) and immunophilin
(Taipale, et aI., 2010). HSP90 chaperone complex acts on its client proteins to
stabilize them and prevent aggregation, facilitate cell membrane crossing,
stabilize conformations and target client proteins for degradation (Taipale, et aI.,
2010). Because HSP90 regulates diverse cellular processes that promote cell
survival and proliferation, it is a good molecular target to sensitize cancer cells to
anticancer drugs. Cisplatin binds to HSP90 at its C-terminus and inhibits its ATP
binding ability (Donnelly and Blagg, 2008; Landriscina, et aI., 2010). In addition to
the C-terminus domain, the N-terminal domain has an ATP binding site that is
highly conserved. HSP90 inhibitors such as geldanamycin and 17-DMAG
compete with ATP for this binding site. ATP binding and hydrolysis is required for
HSP90 function. Several inhibitors of the ATP binding site of HSP90 are
undergoing clinical trials as anticancer agents (Messaoudi, et aI., 2011). In the
current study, I have showed that HSP60 and HSP70 were induced and HSP90
remained unchanged in response to CPA 39
using 17-DMAG potentiated CPA 39

cc. Inhibition of HSP90 activity

cc cytotoxicity in A2780, A2780/CP70 and

SKOV-3 cells. The robust cytotoxicity observed with 17-DMAG co-treatment with
CPA 39

Cc could be due partially to enhanced cellular accumulation of cisplatin.
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In summary, I have showed that co-treatment with HSP90 inhibitor 17DMAG and CPA 39 DC (CPAD 39 DC) may reverse cisplatin resistance in OC
cells independent of p53 status. Co-treatment enhanced cellular accumulation of
cisplatin. Further studies are needed to better understand the precise
mechanisms involved in 17-DMAG enhancement of the CPA 39 DC cytotoxicity.

136

CHAPTER 6
OVERALL DISCUSSION AND CONCLUSIONS
The goal of this research project was to mitigate cisplatin resistance in
OC. I investigated the effect of a new combination of cisplatin, sodium arsenite
and hyperthermia against OC cells. Sodium arsenite alone or combined with
hyperthermia selectively sensitized wild-type p53 expressing human OC cells
(A2780, A2780/CP70, OVCA 420, OVCA 429 and OVCA 433) to cisplatin (Figure
3A). In contrast, only hyperthermia sensitized p53-null (SKOV-3) and p53mutated (OVCAR-3 and OVCA 432) cells to cisplatin (Figure 38). Sodium
arsenite selective sensitization of p53 expressing cells to cisplatin could be due
to its effect on the nucleotide excision repair (NER) pathway that repairs
platinum-DNA damage and confers resistance to cisplatin. Arsenic has been
shown to inhibit induction of the global genome repair - NER protein XPC
(Nollen, et aI., 2009). XPC is intimately involved in the repair of platinum-DNA
damage (Neher, et aI., 2010). P53 is implicated in platinum-DNA repair because
it transcriptionally regulates XPC (Ford, 2005), which is required for efficient
global genome repair. I have shown that cisplatin induces XPC only in wild-type
p53 expressing cells and in tumors derived from p53 expressing A2780/CP70
cells. XPC siRNA transfection enhanced cisplatin cytotoxicity, indicating that
induction of XPC confers resistance to cisplatin. Furthermore, sodium arsenite ±
hyperthermia inhibited XPC in p53 expressing OC
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cells and in tumors derived from p53 expressing A2780/CP70 cells. These data
indicated that sodium arsenite selectively sensitized p53 expressing cells to
cisplatin by suppressing XPC. Inhibition of XPC will decrease the recruitment of
downstream NER proteins and suppress DNA repair (Nollen, et aI., 2009).
In addition to enhanced DNA repair, decreased cellular platinum and
platinum bound to DNA contributes to cisplatin resistance (Parker, et aI., 1991).
Hyperthermia ± sodium arsenite enhanced cellular and platinum bound to DNA in
p53 expressing A2780 and A2780/CP70 cells. Whereas, only hyperthermia
enhanced cellular and platinum bound to DNA in p53 null SKOV-3 cells. Platinum
accumulation in xenograft tumors was enhanced by sodium arsenite cotreatment with cisplatin at 37 or 39 cC. GST activity was not altered by cisplatin
alone or by its combination with sodium arsenite and/or hyperthermia, suggesting
that the GSH/GST system does not contribute to cisplatin resistance in these
cells.
In response to cisplatin treatment, p53 induces G2 arrest by
transcriptionally activating CDKN1A, GADD45 and 14-3-3cr which inhibit cyclin
B/CDK1 to prevent cell cycle progression through G2 phase (Taylor and Stark,
2001). Cell cycle analysis data suggested that A2780 and A2780/CP70 cells
treated with cisplatin ± sodium arsenite at 37 or 39 cc accumulated in the G2/M
compartment 36 h after treatment. Western blot analyses of cyclin A and cyclin B
suggested that sodium arsenite ± hyperthermia is caused cisplatin treated cells
to arrest in mitosis. However, lack of histone H3Ser10P and relative low mitotic
index clearly indicated that cells are not in mitosis. Furthermore, I observed that
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cisplatin alone or combined with sodium arsenite and hyperthermia did not
induce spindle checkpoint protein BUBR1 phosphorylation. Since the spindle
assembly complex is dependent on BUBR1 phosphorylation for it to function,
lack of BUBR1 phosphorylation weakens the mitotic spindle checkpoint and
cause cells to exit mitosis without dividing (McNeely, et aI., 2008b). Similar to a
report by Lanni and Jacks (Lanni and Jacks, 1998), these postmitotic cells had
biochemical properties similar to G1 cells: induction of CDKN1A, stabilization of
cyclin E and hypophosphorylation of pRb. Thus, cells with 2C DNA content that
accumulated in the G2/M compartment were postmitotic or pseudo-G1 cells that
failed to divide in mitosis. These cells underwent apoptosis. These data suggest
a new mechanism by which cisplatin alone or combined with sodium arsenite
and/or hyperthermia induces cell death.
Cisplatin, sodium arsenite and hyperthermia induce stress-mediated cell
death by generating reactive oxygen and electrophile species (Del Razo, et aI.,
2001; Pandita, et aI., 2009). These reactive species can cause oxidative damage
to DNA, protein, RNA and lipids. Stress response proteins promote survival by
refolding unfolded proteins and degrading damaged proteins. These stress
response proteins or heat shock proteins therefore confer resistance to
anticancer drugs (Landriscina, et aI., 2010). In response to cisplatin, sodium
arsenite and hyperthermia treatment, I observed induction of HSP60 and HSP70
in A2780 and A2780/CP70 cells as early as 2 h after treatment and robustly at 24
h. In addition, HSP90 was stabilized in these cells. These data suggested that
cisplatin, sodium arsenite and hyperthermia generated cellular stress that led to
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the induction of stress response proteins. I also observed PARP-1 cleavage at 24
h after treatment, suggesting that apoptotic cell death occurred in response to
cellular stress. HSP90 is ubiquitously expressed in cancer cells and it regulates
signaling pathways, cell survival and proliferation (Taipale, et aI., 2010), making it
a good molecular target in cancer cells. HSP90 inhibitor 17-DMAG greatly
sensitized A2780, A2780/CP70 and SKOV-3 cells to combined cisplatin, sodium
arsenite and hyperthermia (CPA 39°C). This sensitization was associated with
enhanced cellular platinum accumulation.
Cancer cell populations are heterogeneous and not homogenous because
cancer cells frequently undergo mutations and alterations in key genes such as
p53 (Zeimet and Marth, 2003). Immunocytochemistry data suggest that
A2780/CP70 cell population is heterogeneous in p53 expression. About 75% of

the cells expressed functional p53 while 25% did not express the protein. Also,
about 6% of tumors derived from A2780/CP70 cells were p53 null. Presence of
heterogeneity makes it ineffective to treat cancer with a single drug or multiple
drugs aimed at single key regulatory protein such as p53 or a signaling pathway.
Therefore, My findings that combined cisplatin, sodium arsenite and
hyperthermia (CPA 39°C) suppressed DNA repair protein, enhanced cellular
platinum and platinum bound to DNA accumulation, induced cytotoxic cellular
stress, disrupted mitotic spindle checkpoint and caused cells to accumulate in
pseudo-G1 and subsequently undergo apoptosis, indicate that this new
combination chemotherapy has multiple mechanisms of sensitizing cancer cells
to cisplatin and inducing cell death. Thus, this new combination therapy may be
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beneficial clinically in treating patients with cisplatin resistant disease regardless
of the p53 status. Adding 17-DMAG to counteract the heat shock protein
response will potentially reverse cisplatin resistance. Therefore CPA 39°C or
CPA 39 °C plus 17-DMAG delivered intraperitoneally may be useful in increasing
overall survival of DC patients. In the future, in vivo survival studies using the
metastatic DC model and murine HIPEC system is required in order to determine
if this combination chemotherapy is effective in vivo to suppress tumor burden.
Long-term survival data generated from the in vivo studies will be useful in
determining the potential clinical application of the new combination of cisplatin,
sodium arsenite and hyperthermia (CPA 39°C) and also CPA 39 °c plus 17DMAG.
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CHAPTER 7
FUTURE STUDIES
In the future, long-term survival studies are needed to determine response
of peritoneal tumors to the new combination of cisplatin, sodium arsenite and
hyperthermia (CPA 39°C) and also CPA 39 °c plus 17-DMAG. These studies
wi" require a non-invasive method of visualizing the tumors. Therefore, one
means of visualizing is to establish OC cells stably expressing f3, actinpTurboFP635 (katushka) fusion protein. These cells can be injected into the
peritoneum of nude mice to establish metastatic tumors stably expressing red
fluorescent katushka protein. Tumors with red fluorescent katushka protein
should be easily visualized by non-invasive fluorescence imaging. Tumor bearing
mice wi" be treated with cisplatin, sodium arsenite and/or 17-DMAG at 37 or 39
°c for 1 h using the HIPEC model. Mice will be maintained for up to 60 days and
response to chemotherapy wi" be determined by fluorescence imaging of tumors.
The fluorescence intensity wi" be used to calculate the tumor burden. Data
generated from this survival study wi" provide a better understanding of the in

vivo response of peritoneal tumors to this

new combination chemotherapy and its

potential clinical use.
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APPENDIX
Abbreviations
APC

Anaphase promoting complex

APL

Acute promyelocytic leukemia

BSA

Bovine serum albumin

BUBR1

Budding uninhibited by benzimidazoles related 1

CDK

Cyclin dependent kinase

CP

Cisplatin

CP37

Cisplatin at 37°C

CP39

Cisplatin at 39°C

CPA

Cisplatin plus sodium arsenite

CPA37

Cisplatin plus sodium arsenite at 37°C

CPA39

Cisplatin plus sodium arsenite at 39°C

DDB2

DNA damage binding protein 2

DMSO

Dimethyl sulfoxide

17-DMAG

17-(Dimethylaminoethyamino )-17demethoxygeldanamycin

ERCC1

Excision repair cross-complementing 1

FBS

Fetal bovine serum

GADD45

Growth arrest and DNA damage-inducible protein 45

GGR

Global genome repair
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GSH

Glutathione

GST

Glutathione S-transferase

HIPEC

Hyperthermic intraperitoneal chemotherapy

ICP-MS

Inductively coupled plasma mass spectrometry

MSH2

MutS homolog 2 protein

MTI

3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide

NaAs0 2

Sodium arsenite

NER

Nucleotide excision repair

NSC

Non-specific control

OC

Ovarian cancer

PAGE

Polyacrylamide gel electrophoresis

PARP

Poly(ADP-ribose) polymerase

PBS

Phosphate buffered saline

PI

Propidium iodide

p53Ser15P

p53 phosphorylated on Ser15

pRBS807/811 P

Retinoblastoma protein phosphorylated on
Ser807/811

Pt

Patinum

TCR

Transcription Coupled repair

XPA

Xeroderma pigmentosum group A protein

XPC

Xeroderma pigmentosum group C protein
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